Abstract:
Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.

Description:
CROSS REFERENCE TO RELATED APPLICATIONS 
       [0001]    This application is a continuation of U.S. application Ser. No. 11/368,225 filed 3 Mar. 2006, issued as U.S. Pat. No. 7,419,952, which is a continuation of each of U.S. application Ser. No. 10/964,887 filed 15 Oct. 2004, issued as U.S. Pat. No. 7,115,569, and of U.S. application Ser. No. 10/966,337 filed 14 Oct. 2004, issued as U.S. Pat. No. 7,138,375, each of which are continuations of U.S. application Ser. No. 10/187,051 filed 28 Jun. 2002, issued as U.S. Pat. No. 6,989,366, which is a continuation of U.S. application Ser. No. 09/003,869 filed Jan. 7, 1998, issued as U.S. Pat. No. 6,956,026, which claims priority to U.S. Application No. 60/034,905 filed 7 Jan. 1997, U.S. Application No. 60/055,404 filed 8 Aug. 1997, U.S. Application No. 60/066,029 filed 14 Nov. 1997, and U.S. Application No. 60/065,442, filed 14 Nov. 1997. The contents of each of these references are hereby incorporated by reference in their entirety. 
     
    
     FIELD OF THE INVENTION 
       [0002]    The present invention relates to methods for treating conditions or disorders which can be alleviated by reducing food intake comprising administration of an effective amount of an exendin or an exendin agonist alone or in conjunction with other compounds or compositions that affect satiety such as a leptin or an amylin agonist. The methods are useful for treating conditions or disorders, in which the reduction of food intake is of value, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed. 
       BACKGROUND OF THE INVENTION 
       [0003]    The following description summarizes information relevant to the present invention. It is not an admission that any of the information provided herein is prior art to the presently claimed invention, nor that any of the publications specifically or implicitly referenced are prior art to that invention. 
         [0004]    Exendins are peptides that are found in the venom of the Gila-monster, a lizard found in Arizona, and the Mexican Beaded Lizard. Exendin-3 is present in the venom of Heloderma horridum, and exendin-4 is present in the venom of Heloderma suspectum (Eng et al,  J. Biol. Chem.,  265:20259-20262 (1990); Eng et al,  J. Biol. Chem.,  267:7402-7405 (1992)). The exendins have some sequence similarity to several members of the glucagon-like peptide family, with the highest homology, 53%, being to GLP-1[7-36]NH 2  (Göke et al,  J. Biol. Chem.,  268:19650-19655 (1993)). GLP-1[7-36]NH 2 , also known as proglucagon[78-107], has an insulinotropic effect, stimulating insulin secretion from pancreatic β-cells; GLP also inhibits glucagon secretion from pancreatic α-cells (Ørskov et al,  Diabetes,  42:658-661 (1993); D&#39;Alessio et al,  J. Clin. Invest.,  97:133-138 (1996)). GLP-1 is reported to inhibit gastric emptying (Williams et al,  J Clin Endocrinol Metab.,  81(1):327-332 (1996); Wettergren et al,  Dig Dis Sci.,  38(4):665-673 (1993)), and gastric acid secretion. (Schjoldager et al,  Dig Dis Sci.,  34(5):703-708 (1989); O&#39;Halloran et al,  J Endocrinol.,  126(1):169-173 (1990); Wettergren et al,  Dig Dis Sci.,  38(4):665-673 (1993)). GLP-1[7-37], which has an additional glycine residue at its carboxy terminus, also stimulates insulin secretion in humans (Ørskov et al,  Diabetes,  42:658-661 (1993)). A transmembrane G-protein adenylate-cyclase-coupled receptor believed to be responsible for the insulinotropic effect of GLP-1 is reported to have been cloned from a β-cell line (Thorens,  Proc. Natl. Acad. Sci. USA,  89:8641-8645 (1992)). 
         [0005]    Exendin-4 potently binds at GLP-1 receptors on insulin-secreting βTC1 cells, at dispersed acinar cells from guinea pig pancreas, and at parietal cells from stomach; the peptide is also said to stimulate somatostatin release and inhibit gastrin release in isolated stomachs (Göke et al,  J. Biol. Chem.,  268:19650-19655 (1993); Schepp et al,  Eur. J. Pharmacol.,  69:183-191 (1994); Eissele et al,  Life Sci.,  55:629-634 (1994)). Exendin-3 and exendin-4 were reported to stimulate cAMP production in, and amylase release from, pancreatic acinar cells (Malhotra et al,  Regulatory Peptides,  41:149-156 (1992); Raufman et al,  J. Biol. Chem.,  267:21432-21437 (1992); Singh et al,  Regul. Pept.,  53:47-59 (1994)). The use of exendin-3 and exendin-4 as insulinotrophic agents for the treatment of diabetes mellitus and the prevention of hyperglycemia has been proposed (Eng, U.S. Pat. No. 5,424,286). 
         [0006]    C-terminally truncated exendin peptides such as exendin[9-39], a carboxyamidated molecule, and fragments 3-39 through 9-39 have been reported to be potent and selective antagonists of GLP-1 (Göke et al,  J. Biol. Chem.,  268:19650-19655 (1993); Raufman et al,  J. Biol. Chem.,  266:2897-2902, 1991; Schepp et al,  Eur. J. Pharm.,  269:183-91, 1994; Montrose-Rafizadeh et al,  Diabetes,  45(Suppl. 2):152A, 1996). Exendin[9-39] is said to block endogenous GLP-1 in vivo, resulting in reduced insulin secretion. (Wang et al,  J. Clin. Invest.,  95:417-21, 1995; D&#39;Alessio et al,  J. Clin. Invest.,  97:133-38, 1996). The receptor apparently responsible for the insulinotropic effect of GLP-1 has reportedly been cloned from rat pancreatic islet cell (Thorens,  Proc. Natl. Acad. Sci. USA  89:8641-8645, 1992). Exendins and exendin[9-39] are said to bind to the cloned GLP-1 receptor (rat pancreatic β-cell GLP-1 receptor (Fehmann et al,  Peptides  15(3):453-6, 1994) and human GLP-1 receptor (Thorens et al,  Diabetes  42(11):1678-82, 1993). In cells transfected with the cloned GLP-1 receptor, exendin-4 is reportedly an agonist, i.e., it increases cAMP, while exendin[9-39] is identified as an antagonist, i.e., it blocks the stimulatory actions of exendin-4 and GLP-1. Id. 
         [0007]    Exendin[9-39] is also reported to act as an antagonist of the full length exendins, inhibiting stimulation of pancreatic acinar cells by exendin-3 and exendin-4 (Raufman et al,  J. Biol. Chem.  266:2897-902, 1991; Raufman et al,  J. Biol. Chem.,  266:21432-37, 1992). It is also reported that exendin[9-39] inhibits the stimulation of plasma insulin levels by exendin-4, and inhibits the somatostatin release-stimulating and gastrin release-inhibiting activities of exendin-4 and GLP-1 (Kolligs et al,  Diabetes,  44:16-19, 1995; Eissele et al,  Life Sciences,  55:629-34, 1994). 
         [0008]    Exendins have recently been found to inhibit gastric emptying (U.S. Ser. No. 08/694,954, filed Aug. 8, 1996, (abandoned, but see, U.S. Pat. No. 6,858,576) which enjoys common ownership with the present invention and is hereby incorporated by reference). 
         [0009]    Exendin [9-39] has been used to investigate the physiological relevance of central GLP-1 in control of food intake (Turton et al,  Nature,  379:69-72, 1996). GLP-1 administered by intracerebroventricular injection inhibits food intake in rats. This satiety-inducing effect of GLP-1 delivered ICV is reported to be inhibited by ICV injection of exendin [9-39] (Turton, supra). However, it has been reported that GLP-1 does not inhibit food intake in mice when administered by peripheral injection (Turton,  Nature,  379:69-72, 1996; Bhavsar,  Soc. Neurosci. Abstr.,  21:460 (188.8), 1995). 
         [0010]    Obesity, excess adipose tissue, is becoming increasingly prevalent in developed societies. For example, approximately 30% of adults in the U.S. were estimated to be 20 percent above desirable body weight—an accepted measure of obesity sufficient to impact a health risk (H ARRISON&#39;S  P RINCIPLES OF  I NTERNAL  M EDICINE  12th Edition, McGraw Hill, Inc. (1991) p. 411). The pathogenesis of obesity is believed to be multifactorial but the basic problem is that in obese subjects food intake and energy expenditure do not come into balance until there is excess adipose tissue. Attempts to reduce food intake, or hypernutrition, are usually fruitless in the medium term because the weight loss induced by dieting results in both increased appetite and decreased energy expenditure (Leibel et al, (1995)  New England Journal of Medicine  322: 621-628). The intensity of physical exercise required to expend enough energy to materially lose adipose mass is too great for most people to undertake on a sufficiently frequent basis. Thus, obesity is currently a poorly treatable, chronic, essentially intractable metabolic disorder. Not only is obesity itself believed by some to be undesirable for cosmetic reasons, but obesity also carries serious risk of co-morbidities including, Type 2 diabetes, increased cardiac risk, hypertension, atherosclerosis, degenerative arthritis, and increased incidence of complications of surgery involving general anesthesia. Obesity due to hypernutrition is also a risk factor for the group of conditions called insulin resistance syndrome, or “syndrome X.” In syndrome X, it has been reported that there is a linkage between insulin resistance and hypertension. (Watson N. and Sandler M.,  Curr. Med. Res. Opin.,  12(6):374-378 (1991); Kodama J. et al., Diabetes Care, 13(11):1109-1111 (1990); Lithell et al.,  J. Cardiovasc. Pharmacol.,  15 Suppl. 5:S46-S52 (1990)). 
         [0011]    In those few subjects who do succeed in losing weight, by about 10 percent of body weight, there can be striking improvements in co-morbid conditions, most especially Type 2 diabetes in which dieting and weight loss are the primary therapeutic modality, albeit relatively ineffective in many patients for the reasons stated above. Reducing food intake in obese subjects would decrease the plasma glucose level, the plasma lipid level, and the cardiac risk in these subjects. Hypernutrition is also the result of, and the psychological cause of, many eating disorders. Reducing food intake would also be beneficial in the treatment of such disorders. 
         [0012]    Thus, it can be appreciated that an effective means to reduce food intake is a major challenge and a superior method of treatment would be of great utility. Such a method, and compounds and compositions which are useful therefor, have been invented and are described and claimed herein. 
       SUMMARY OF THE INVENTION 
       [0013]    The present invention concerns the surprising discovery that exendins and exendin agonists have a profound and prolonged effect on inhibiting food intake. 
         [0014]    The present invention is directed to novel methods for treating conditions or disorders associated with hypernutrition, comprising the administration of an exendin, for example, exendin-3 [SEQ ID NO: 1: His Ser Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser], or exendin-4 [SEQ ID NO: 2: His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser], or other compounds which effectively bind to the receptor at which exendin exerts its action on reducing food intake. These methods will be useful in the treatment of, for example, obesity, diabetes, including Type II or non-insulin dependent diabetes, eating disorders, and insulin-resistance syndrome. 
         [0015]    In a first aspect, the invention features a method of treating conditions or disorders which can be alleviated by reducing food intake in a subject comprising administering to the subject a therapeutically effective amount of an exendin or an exendin agonist. By an “exendin agonist” is meant a compound that mimics the effects of exendin on the reduction of food intake by binding to the receptor or receptors where exendin causes this effect. Preferred exendin agonist compounds include those described in U.S. Provisional Patent Application Ser. No. 60/055,404, entitled, “Novel Exendin Agonist Compounds,” filed Aug. 8, 1997 (see U.S. Pat. No. 7,157,555); U.S. Provisional Patent Application Ser. No. 60/065,442, entitled, “Novel Exendin Agonist Compounds,” filed Nov. 14, 1997 (see U.S. Pat. No. 7,223,725); and U.S. Provisional Patent Application Ser. No. 60/066,029, entitled, “Novel Exendin Agonist Compounds,” filed Nov. 14, 1997 (see U.S. Pat. No. 7,220,721); all of which enjoy common ownership with the present application and all of which are incorporated by this reference into the present application as though fully set forth herein. By “condition or disorder which can be alleviated by reducing food intake” is meant any condition or disorder in a subject that is either caused by, complicated by, or aggravated by a relatively high food intake, or that can be alleviated by reducing food intake. Such conditions or disorders include, but are not limited to, obesity, diabetes, including Type II diabetes, eating disorders, and insulin-resistance syndrome. 
         [0016]    Thus, in a first embodiment, the present invention provides a method for treating conditions or disorders which can be alleviated by reducing food intake in a subject comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist. Preferred exendin agonist compounds include those described in U.S. Provisional Patent Application Ser. Nos. 60/055,404; 60/065,442; and 60/066,029 (see U.S. Pat. Nos. 7,157,555; 7,223,725; and 7,220,721, respectively), which have been incorporated by reference in the present application. Preferably, the subject is a vertebrate, more preferably a mammal, and most preferably a human. In preferred aspects, the exendin or exendin agonist is administered parenterally, more preferably by injection. In a most preferred aspect, the injection is a peripheral injection. Preferably, about 10 μg-30 μg to about 5 mg of the exendin or exendin agonist is administered per day. More preferably, about 10-30 μg to about 2 mg, or about 10-30 μg to about 1 mg of the exendin or exendin agonist is administered per day. Most preferably, about 30 μg to about 500 μg of the exendin or exendin agonist is administered per day. 
         [0017]    In various preferred embodiments of the invention, the condition or disorder is obesity, diabetes, preferably Type II diabetes, an eating disorder, or insulin-resistance syndrome. 
         [0018]    In other preferred aspects of the invention, a method is provided for reducing the appetite of a subject comprising administering to said subject an appetite-lowering amount of an exendin or an exendin agonist. 
         [0019]    In yet other preferred aspects, a method is provided for lowering plasma lipids comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist. 
         [0020]    The methods of the present invention may also be used to reduce the cardiac risk of a subject comprising administering to said subject a therapeutically effective amount of an exendin or an exendin agonist. In one preferred aspect, the exendin or exendin agonist used in the methods of the present invention is exendin-3. In another preferred aspect, said exendin is exendin-4. Other preferred exendin agonists include exendin-4 (1-30) [SEQ ID NO: 6: His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly], exendin-4 (1-30) amide [SEQ ID NO: 7: His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly-NH 2 ], exendin-4 (1-28) amide [SEQ ID NO: 40: His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn-NH 2 ],  14 Leu,  25 Phe exendin-4 amide [SEQ ID NO: 9: His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser-NH 2 ],  14 Leu,  25 Phe exendin-4 (1-28) amide [SEQ ID NO: 41: His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn-NH 2 ], and  14 Leu,  22 Ala,  25 Phe exendin-4 (1-28) amide [SEQ ID NO: 8: His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Ala Ile Glu Phe Leu Lys Asn-NH 2 ]. 
         [0021]    In the methods of the present invention, the exendins and exendin agonists may be administered separately or together with one or more other compounds and compositions that exhibit a long term or short-term satiety action, including, but not limited to other compounds and compositions that comprise an amylin agonist, cholecystokinin (CCK), or a leptin (ob protein). Suitable amylin agonists include, for example, [ 25,28,29 Pro-]-human amylin (also known as “pramlintide,” and previously referred to as “AC-137”) as described in “Amylin Agonist Peptides and Uses Therefor,” U.S. Pat. No. 5,686,511, issued Nov. 11, 1997, and salmon calcitonin. The CCK used is preferably CCK octopeptide (CCK-8). Leptin is discussed in, for example, Pelleymounter et al.,  Science,  269:540-43 (1995); Halaas et al.,  Science,  269:543-46 (1995); and Campfield et al.  Eur. J. Pharmac.,  262:133-41 (1994). 
         [0022]    In other embodiments of the invention is provided a pharmaceutical composition for use in the treatment of conditions or disorders which can be alleviated by reducing food intake comprising a therapeutically effective amount of an exendin or exendin agonist in association with a pharmaceutically acceptable carrier. Preferably, the pharmaceutical composition comprises a therapeutically effective amount for a human subject. 
         [0023]    The pharmaceutical composition may preferably be used for reducing the appetite of a subject, reducing the weight of a subject, lowering the plasma lipid level of a subject, or reducing the cardiac risk of a subject. Those of skill in the art will recognize that the pharmaceutical composition will preferably comprise a therapeutically effective amount of an exendin or exendin agonist to accomplish the desired effect in the subject. 
         [0024]    The pharmaceutical compositions may further comprise one or more other compounds and compositions that exhibit a long-term or short-term satiety action, including, but not limited to other compounds and compositions that comprise an amylin agonist, CCK, preferably CCK-8, or leptin. Suitable amylin agonists include, for example, [252829 Pro]-human amylin and salmon calcitonin. 
         [0025]    In one preferred aspect, the pharmaceutical composition comprises exendin-3. In another preferred aspect, the pharmaceutical composition comprises exendin-4. In other preferred aspects, the pharmaceutical compositions comprises a peptide selected from: exendin-4 (1-30), exendin-4 (1-30) amide, exendin-4 (1-28) amide,  14 Leu,  25 Phe exendin-4 amide,  14 Leu,  25 Phe exendin-4 (1-28) amide, and  14 Leu,  22 Ala,  25 Phe exendin-4 (1-28) amide. 
     
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
         [0026]      FIG. 1  is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of exendin-4 and GLP-1. 
           [0027]      FIG. 2  is a graphical depiction of the change of food intake in obese mice after intraperitoneal injection of exendin-4. 
           [0028]      FIG. 3  is a graphical depiction of the change of food intake in rats after intracerebroventricular injection of exendin-4 
           [0029]      FIG. 4  is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of exendin-4 (1-30) (“Compound 1”). 
           [0030]      FIG. 5  is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of exendin-4 (1-30) amide (“Compound 2”). 
           [0031]      FIG. 6  is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of exendin-4 (1-28) amide (“Compound 3”). 
           [0032]      FIG. 7  is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of  14 Leu,  25 Phe exendin-4 (1-28) amide (“Compound 5”). 
           [0033]      FIG. 8  is a graphical depiction of the change of food intake in normal mice after intraperitoneal injection of  14 Leu,  22 Ala,  25 Phe exendin-4 (1-28) amide (“Compound 6”). 
           [0034]      FIG. 9  depicts the amino acid sequences for certain exendin agonist compounds comprising the amino acid sequence: Xaa 1  Gly Xaa 3  Gly Thr Xaa 4  Xaa 5  Xaa 6  Xaa 7  Xaa 8  Ser Lys Gln Xaa 9  Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Xaa 13  Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Xaa 18 -NH 2 , that are useful in the present invention [SEQ ID NOs. 9-22]. 
           [0035]      FIG. 10  depicts the amino acid sequences for certain exendin agonist compounds comprising the amino acid sequence: His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Xaa 9  Glu Glu Glu Ala Val Arg Leu Xaa 10  Xaa 11  Xaa 12  Xaa 13  Leu Lys Asn Gly Gly Xaa 14  Ser Ser Gly Ala Xaa 15  Xaa 16  Xaa 17  Ser-NH 2 , that are useful in the present invention [SEQ ID NOs. 23-39]. 
       
    
    
     DESCRIPTION OF THE INVENTION 
       [0036]    Exendins and exendin agonists are useful as described herein in view of their pharmacological properties. Activity as exendin agonists can be indicated by activity in the assays described below. Effects of exendins or exendin agonists on reducing food intake can be identified, evaluated, or screened for, using the methods described in the Examples below, or other methods known in the art for determining effects on food intake or appetite. 
         [0037]    Exendin agonist compounds are those described in U.S. Provisional Application No. 60/055,404 (see U.S. Pat. No. 7,223,725), including compounds of the formula (I) [SEQ ID NO: 3]: 
         [0000]                        1                 5                     10           Xaa 1  Xaa 2  Xaa 3  Gly Thr Xaa 4  Xaa 5  Xaa 6  Xaa 7  Xaa 8                          15                  20       Ser Lys Gln Xaa 9  Glu Glu Glu Ala Val Arg Leu                       25                  30       Xaa 10  Xaa 11  Xaa 12  Xaa 13  Leu Lys Asn Gly Gly Xaa 14                     35       Ser Ser Gly Ala Xaa 15  Xaa 16  Xaap 17  Xaa 18 -Z            
wherein Xaa 1  is His, Arg or Tyr; Xaa 2  is Ser, Gly, Ala or Thr; Xaa 3  is Asp or Glu; Xaa 4  is Phe, Tyr or naphthylalanine; Xaa 5  is Thr or Ser; Xaa 6  is Ser or Thr; Xaa 7  is Asp or Glu; Xaa 8  is Leu, Ile, Val, pentylglycine or Met; Xaa 9  is Leu, Ile, pentylglycine, Val or Met; Xaa 10  is Phe, Tyr or naphthylalanine; Xaa 11  is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met; Xaa 12  is Glu or Asp; Xaa 13  is Trp, Phe, Tyr, or naphthylalanine; Xaa 14 , Xaa 15 , Xaa 16  and Xaa 17  are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine or N-alkylalanine; Xaa 18  is Ser, Thr or Tyr; and Z is —OH or —NH 2 ; with the proviso that the compound is not exendin-3 or exendin-4.
 
         [0038]    Preferred N-alkyl groups for N-alkylglycine, N-alkylpentylglycine and N-alkylalanine include lower alkyl groups preferably of 1 to about 6 carbon atoms, more preferably of 1 to 4 carbon atoms. Suitable compounds include those listed in  FIGS. 9 and 10  having amino acid sequences of SEQ ID NOs. 9 to 39. 
         [0039]    Preferred exendin agonist compounds include those wherein Xaa 1  is His or Tyr. More preferably Xaa 1  is His. 
         [0040]    Preferred are those compounds wherein Xaa 2  is Gly. 
         [0041]    Preferred are those compounds wherein Xaa 9  is Leu, pentylglycine or Met. 
         [0042]    Preferred compounds include those wherein Xaa 13  is Trp or Phe. 
         [0043]    Also preferred are compounds where Xaa 4  is Phe or naphthylalanine; Xaa 11  is Ile or Val and Xaa 14 , Xaa 15 , Xaa 16  and Xaa 17  are independently selected from Pro, homoproline, thioproline or N-alkylalanine. Preferably N-alkylalanine has a N-alkyl group of 1 to about 6 carbon atoms. 
         [0044]    According to an especially preferred aspect, Xaa 15 , Xaa 16  and Xaa 17  are the same amino acid reside. 
         [0045]    Preferred are compounds wherein Xaa 18  is Ser or Tyr, more preferably Ser. Preferably Z is —NH 2 . 
         [0046]    According to one aspect, preferred are compounds of formula (I) wherein Xaa 1  is His or Tyr, more preferably His; Xaa 2  is Gly; Xaa 4  is Phe or naphthylalanine; Xaa 9  is Leu, pentylglycine or Met; Xaa 10  is Phe or naphthylalanine; Xaa 11  is Ile or Val; Xaa 14 , Xaa 15 , Xaa 16  and Xaa 17  are independently selected from Pro, homoproline, thioproline or N-alkylalanine; and Xaa 18  is Ser or Tyr, more preferably Ser. More preferably Z is —NH 2 . 
         [0047]    According to an especially preferred aspect, especially preferred compounds include those of formula (I) wherein: Xaa 1  is His or Arg; Xaa 2  is Gly; Xaa 3  is Asp or Glu; Xaa 4  is Phe or napthylalanine; Xaa 5  is Thr or Ser; Xaa 6  is Ser or Thr; Xaa 7  is Asp or Glu; Xaa 8  is Leu or pentylglycine; Xaa 9  is Leu or pentylglycine; Xaa 10  is Phe or naphthylalanine; Xaa 11  is Ile, Val or t-butyltylglycine; Xaa 12  is Glu or Asp; Xaa 13  is Trp or Phe; Xaa 14 , Xaa 15 , Xaa 16 , and Xaa 17  are independently Pro, homoproline, thioproline, or N-methylalanine; Xaa 18  is Ser or Tyr: and Z is —OH or —NH 2 ; with the proviso that the compound does not have the formula of either SEQ. ID. NOS: 1 or 2. More preferably Z is —NH 2 . Especially preferred compounds include those having the amino acid sequence of SEQ. ID. NOS:9, 10, 21, 22, 23, 26, 28, 34, 35 and 39. 
         [0048]    According to an especially preferred aspect, provided are compounds where Xaa 9  is Leu, Ile, Val or pentylglycine, more preferably Leu or pentylglycine, and Xaa 13  is Phe, Tyr or naphthylalanine, more preferably Phe or naphthylalanine. These compounds will exhibit advantageous duration of action and be less subject to oxidative degration, both in vitro and in vivo, as well as during synthesis of the compound. 
         [0049]    Exendin agonist compounds also include those described in U.S. Provisional Application No. 60/065,442 (see U.S. Pat. No. 7,223,725), including compounds of the formula (II) [SEQ ID NO: 4]: 
         [0000]                        Xaa 1  Xaa 2  Xaa 3  Gly Xaa 5  Xaa 6  Xaa 7  Xaa 8  Xaa 9  Xaa 10                     Xaa 11  Xaa 12  Xaa 13  Xaa 14  Xaa 15  Xaa 16  Xaa 17  Ala Xaa 19                 Xaa 20  Xaa 21  Xaa 22  Xaa 23  Xaa 24  Xaa 25  Xaa 26  Xaa 27                 Xaa 28 -Z 1 ;            
wherein Xaa 1  is His, Arg or Tyr; Xaa 2  is Ser, Gly, Ala or Thr; Xaa 3  is Asp or Glu; Xaa 5  is Ala or Thr; Xaa 6  is Ala, Phe, Tyr or naphthylalanine; Xaa 7  is Thr or Ser; Xaa 8  is Ala, Ser or Thr; Xaa 9  is Asp or Glu; Xaa 10  is Ala, Leu, Ile, Val, pentylglycine or Met; Xaa 11  is Ala or Ser; Xaa 12  is Ala or Lys; Xaa 13  is Ala or Gln; Xaa 14  is Ala, Leu, Ile, pentylglycine, Val or Met; Xaa 15  is Ala or Glu; Xaa 16  is Ala or Glu; Xaa 17  is Ala or Glu; Xaa 19  is Ala or Val; Xaa 20  is Ala or Arg; Xaa 21  is Ala or Leu; Xaa 22  is Ala, Phe, Tyr or naphthylalanine; Xaa 23  is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met; Xaa 24  is Ala, Glu or Asp; Xaa 25  is Ala, Trp, Phe, Tyr or naphthylalanine; Xaa 26  is Ala or Leu; Xaa 27  is Ala or Lys; Xaa 28  is Ala or Asn; Z, is —OH, —NH 2 , Gly-Z 2 , Gly Gly-Z 2 , Gly Gly Xaa 31 -Z 2 , Gly Gly Xaa 31  Ser-Z 2 , Gly Gly Xaa 31  Ser Ser-Z 2 , Gly Gly Xaa 31  Ser Ser Gly-Z 2 , Gly Gly Xaa 31  Ser Ser Gly Ala-Z 2 , Gly Gly Xaa 31  Ser Ser Gly Ala Xaa 36 -Z 2 , Gly Gly Xaa 31  Ser Ser Gly Ala Xaa 36  Xaa 37 -Z 2  or Gly Gly Xaa3 1  Ser Ser Gly Ala Xaa 36  Xaa 37  Xaa 38 -Z 2 ; wherein Xaa 31 , Xaa 36 , Xaa 37  and Xaa 38  are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine or N-alkylalanine; and Z 2  is OH or NH 2 ; provided that no more than three of Xaa 3 , Xaa 5 , Xaa 6 , Xaa 8 , Xaa 10 , Xaa 11 , Xaa 12 , Xaa 13 , Xaa 14 , Xaa 15 , Xaa 16 , Xaa 17 , Xaa 19 , Xaa 20 , Xaa 21 , Xaa 24 , Xaa 25 , Xaa 26 , Xaa 27  and Xaa 28 , are Ala. Preferred N-alkyl groups for N-alkylglycine, N-alkylpentylglycine and N-alkylalanine include lower alkyl groups preferably of 1 to about 6 carbon atoms, more preferably of 1 to 4 carbon atoms.
 
         [0050]    Preferred exendin agonist compounds include those wherein Xaa 1  is His or Tyr. More preferably Xaa 1  is His. 
         [0051]    Preferred are those compounds wherein Xaa 2  is Gly. 
         [0052]    Preferred are those compounds wherein Xaa 14  is Leu, pentylglycine or Met. 
         [0053]    Preferred compounds are those wherein Xaa 25  is Trp or Phe. 
         [0054]    Preferred compounds are those where Xaa 6  is Phe or naphthylalanine; Xaa 22  is Phe or naphthylalanine and Xaa 23  is Ile or Val. 
         [0055]    Preferred are compounds wherein Xaa 31 , Xaa 36 , Xaa 37 , and Xaa 38  are independently selected from Pro, homoproline, thioproline and N-alkylalanine. 
         [0056]    Preferably Z 1  is —NH 2 . 
         [0057]    Preferable Z 2  is —NH 2 . 
         [0058]    According to one aspect, preferred are compounds of formula (II) wherein Xaa 1  is His or Tyr, more preferably His; Xaa 2  is Gly; Xaa 6  is Phe or naphthylalanine; Xaa 14  is Leu, pentylglycine or Met; Xaa 22  is Phe or naphthylalanine; Xaa 23  is Ile or Val; Xaa 31 , Xaa 36 , Xaa 37  and Xaa 38  are independently selected from Pro, homoproline, thioproline or N-alkylalanine. More preferably Z 1  is —NH 2 . 
         [0059]    According to an especially preferred aspect, especially preferred compounds include those of formula (II) wherein: Xaa 1  is His or Arg; Xaa 2  is Gly or Ala; Xaa 3  is Asp or Glu; Xaa 5  is Ala or Thr; Xaa 6  is Ala, Phe or naphthylalanine; Xaa 7  is Thr or Ser; Xaa 8  is Ala, Ser or Thr; Xaa 9  is Asp or Glu; Xaa 10  is Ala, Leu or pentylglycine; Xaa 11  is Ala or Ser; Xaa 12  is Ala or Lys; Xaa 13  is Ala or Gln; Xaa 14  is Ala, Leu or pentylglycine; Xaa 15  is Ala or Glu; Xaa 16  is Ala or Glu; Xaa 17  is Ala or Glu; Xaa 19  is Ala or Val; Xaa 20  is Ala or Arg; Xaa 21  is Ala or Leu; Xaa 22  is Phe or naphthylalanine; Xaa 23  is Ile, Val or tert-butylglycine; Xaa.sub.24 is Ala, Glu or Asp; Xaa 25  is Ala, Trp or Phe; Xaa 26  is Ala or Leu; Xaa 27  is Ala or Lys; Xaa 28  is Ala or Asn; Z, is OH, NH 2 , Gly-Z 2 , Gly Gly-Z 2 , Gly Gly Xaa 31 -Z 2 , Gly Gly Xaa 31  Ser-Z 2 , Gly Gly Xaa 31  Ser Ser-Z 2 , Gly Gly Xaa 31  Ser Ser Gly-Z 2 , Gly Gly Xaa 31  Ser Ser Gly Ala-Z 2 , Gly Gly Xaa 31  Ser Ser Gly Ala Xaa 36 -Z 2 , Gly Gly Xaa 31  Ser Ser Gly Ala Xaa 36  Xaa 37 -Z 2 , Gly Gly Xaa 31  Ser Ser Gly Ala Xaa 36  Xaa 37  Xaa 38 -Z 2 ; Xaa 31 , Xaa 36 , Xaa 37  and Xaa 38  being independently Pro homoproline, thioproline or N-methylalanine; and Z 2  being —OH or —NH 2 ; provided that no more than three of Xaa 3 , Xaa 5 , Xaa 6 , Xaa 8 , Xaa 10 , Xaa 11 , Xaa 12 , Xaa 13 , Xaa 14 , Xaa 15 , Xaa 16 , Xaa 17 , Xaa 19 , Xaa 20 , Xaa 21 , Xaa 24 , Xaa 25 , Xaa 26 , Xaa 27  and Xaa 28  are Ala. Especially preferred compounds include those having the amino acid sequence of SEQ ID NOs. 40-61. 
         [0060]    According to an especially preferred aspect, provided are compounds where Xaa 14  is Leu, Ile, Val or pentylglycine, more preferably Leu or pentylglycine, and Xaa 25  is Phe, Tyr or naphthylalanine, more preferably Phe or naphthylalanine. These compounds will be less susceptive to oxidative degration, both in vitro and in vivo, as well as du-ring synthesis of the compound. 
         [0061]    Exendin agonist compounds also include those described in U.S. Provisional Application No. 60/066,029 (see U.S. Pat. No. 7,220,721), including compounds of the formula (III) [SEQ ID NO: 5]: 
         [0000]                        Xaa 1  Xaa 2  Xaa 3  Xaa 4  Xaa 5  Xaa 6  Xaa 7  Xaa 8  Xaa 9  Xaa 10                     Xaa 11  Xaa 12  Xaa 13  Xaa 14  Xaa 15  Xaa 16  Xaa 17  Ala               Xaa 19  Xaa 20  Xaa 21  Xaa 22  Xaa 23  Xaa 24  Xaa 25  Xaa 26                 Xaa 27  Xaa 28 -Z 1 ;            
wherein Xaa 1  is His, Arg, Tyr, Ala, Norval, Val or Norleu; Xaa 2  is Ser, Gly, Ala or Thr; Xaa 3  is Ala, Asp or Glu; Xaa 4  is Ala, Norval, Val, Norleu or Gly; Xaa 5  is Ala or Thr; Xaa 6  is Phe, Tyr or naphthylalanine; Xaa 7  is Thr or Ser; Xaa 8  is Ala, Ser or Thr; Xaa 9  is Ala, Norval, Val, Norleu, Asp or Glu; Xaa 10  is Ala, Leu, Ile, Val, pentylglycine or Met; Xaa 11  is Ala or Ser; Xaa 12  is Ala or Lys; Xaa 13  is Ala or Gln; Xaa 14  is Ala, Leu, Ile, pentylglycine, Val or Met; Xaa 15  is Ala or Glu; Xaa 16  is Ala or Glu; Xaa 17  is Ala or Glu; Xaa 19  is Ala or Val; Xaa 20  is Ala or Arg; Xaa 21  is Ala or Leu; Xaa 22  is Phe, Tyr or naphthylalanine; Xaa 23  is Ile, Val, Leu, pentylglycine, tert-butylglycine or Met; Xaa 24  is Ala, Glu or Asp; Xaa 25  is Ala, Trp, Phe, Tyr or naphthylalanine; Xaa 26  is Ala or Leu; Xaa 27  is Ala or Lys; Xaa 28  is Ala or Asn; Z, is —OH, —NH 2 , Gly-Z 2 , Gly Gly-Z 2 , Gly Gly Xaa 31 -Z 2 , Gly Gly Xaa 31  Ser-Z 2 , Gly Gly Xaa 31  Ser Ser-Z 2 , Gly Gly Xaa 31  Ser Ser Gly-Z 2 , Gly Gly Xaa 31  Ser Ser Gly Ala-Z 2 , Gly Gly Xaa 31  Ser Ser Gly Ala Xaa 36 -Z 2 , Gly Gly Xaa 31  Ser Ser Gly Ala Xaa 36  Xaa 37 -Z 2 , Gly Gly Xaa 31  Ser Ser Gly Ala Xaa 36  Xaa 37  Xaa 38 -Z 2  or Gly Gly Xaa 31  Ser Ser Gly Ala Xaa 36  Xaa 37  Xaa 38  Xaa 39 -Z 2 ; wherein Xaa 31 , Xaa 36 , Xaa 37  and Xaa 38  are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-alkylglycine, N-alkylpentylglycine or N-alkylalanine; Xaa 39  is Ser or Tyr; and Z 2  is —OH or —NH 2 ; provided that no more than three of Xaa 3 , Xaa 4 , Xaa 5 , Xaa 6 , Xaa 8 , Xaa 9 , Xaa 10 , Xaa 11 , Xaa 12 , Xaa 13 , Xaa 14 , Xaa 15 , Xaa 16 , Xaa 17 , Xaa 19 , Xaa 20 , Xaa 21 , Xaa 24 , Xaa 25 , Xaa 26 , Xaa 27  and Xaa 28  are Ala; and provided also that, if Xaa 1  is His, Arg or Tyr, then at least one of Xaa 3 , Xaa 4  and Xaa 9  is Ala.
 
         [0062]    In accordance with the present invention and as used herein, the following terms are defined to have the following meanings, unless explicitly stated otherwise. 
         [0063]    The term “amino acid” refers to natural amino acids, unnatural amino acids, and amino acid analogs, all in their D and L stereoisomers if their structure allow such stereoisomeric forms. Natural amino acids include alanine (Ala), arginine (Arg), asparagine (Asn), aspartic acid (Asp), cysteine (Cys), glutamine (Gln), glutamic acid (Glu), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), Lysine (Lys), methionine (Met), phenylalanine (Phe), proline (Pro), serine (Ser), threonine (Thr), typtophan (Trp), tyrosine (Tyr) and valine (Val). Unnatural amino acids include, but are not limited to azetidinecarboxylic acid, 2-aminoadipic acid, 3-aminoadipic acid, beta-alanine, aminopropionic acid, 2-aminobutyric acid, 4-aminobutyric acid, 6-aminocaproic acid, 2-aminoheptanoic acid, 2-aminoisobutyric acid, 3-aminoisbutyric acid, 2-aminopimelic acid, tertiary-butylglycine, 2,4-diaminoisobutyric acid, desmosine, 2,2′-diaminopimelic acid, 2,3-diaminopropionic acid, N-ethylglycine, N-ethylasparagine, homoproline, hydroxylysine, allo-hydroxylysine, 3-hydroxyproline, 4-hydroxyproline, isodesmosine, allo-isoleucine, N-methylalanine, N-methylglycine, N-methylisoleucine, N-methylpentylglycine, N-methylvaline, naphthalanine, norvaline, norleucine, ornithine, pentylglycine, pipecolic acid and thioproline. Amino acid analogs include the natural and unnatural amino acids which are chemically blocked, reversibly or irreversibly, or modified on their N-terminal amino group or their side-chain groups, as for example, methionine sulfoxide, methionine sulfone, S-(carboxymethyl)-cysteine, S-(carboxymethyl)-cysteine sulfoxide and S-(carboxymethyl)-cysteine sulfone. 
         [0064]    The term “amino acid analog” refers to an amino acid wherein either the C-terminal carboxy group, the N-terminal amino group or side-chain functional group has been chemically codified to another functional group. For example, aspartic acid-(beta-methyl ester) is an amino acid analog of aspartic acid; N-ethylglycine is an amino acid analog of glycine; or alanine carboxamide is an amino acid analog of alanine. 
         [0065]    The term “amino acid residue” refers to radicals having the structure: (1) —C(O)—R—NH—, wherein R typically is —CH(R′)—, wherein R′ is an amino acid side chain, typically H or a carbon containing substitutent; or (2), 1 wherein p is 1, 2 or 3 representing the azetidinecarboxylic acid, proline or pipecolic acid residues, respectively. 
         [0066]    The term “lower” referred to herein in connection with organic radicals such as alkyl groups defines such groups with up to and including about 6, preferably up to and including 4 and advantageously one or two carbon atoms. Such groups may be straight chain or branched chain. 
         [0067]    “Pharmaceutically acceptable salt” includes salts of the compounds described herein derived from the combination of such compounds and an organic or inorganic acid. In practice the use of the salt form amounts to use of the base form. The compounds are useful in both free base and salt form. 
         [0068]    In addition, the following abbreviations stand for the following: “ACN” or “CH 3 CN” refers to acetonitrile. Boc”, “tBoc” or “Tboc” refers to t-butoxy carbonyl. “DCC” refers to N,N′-dicyclohexylcarbodiimide. “Fmoc” refers to fluorenylmethoxycarbonyl. “HBTU” refers to 2-(1H-benzotriazol-1-yl)-1,1,3,3,-tetramethyluronium hexafluorophosphate. “HOBt” refers to 1-hydroxybenzotriazole monohydrate. “homoP” or hpro” refers to homoproline. “MeAla” or “Nme” refers to N-methylalanine. “naph” refers to naphthylalanine. “pG” or pGly” refers to pentylglycine. “tBuG” refers to tertiary-butylglycine. “ThioP” or tPro” refers to thioproline. “3Hyp” refers to 3-hydroxyproline. “4Hyp” refers to 4-hydroxyproline. “NAG” refers to N-alkylglycine. “NAPG” refers to N-alkylpentylglycine. “Norval” refers to norvaline. “Norleu” refers to norleucine. 
         [0069]    The exendins and exendin agonists described herein may be prepared using standard solid-phase peptide synthesis techniques and preferably an automated or semiautomated peptide synthesizer. Typically, using such techniques, an α-N-carbamoyl protected amino acid and an amino acid attached to the growing peptide chain on a resin are coupled at room temperature in an inert solvent such as dimethylformamide, N-methylpyrrolidinone or methylene chloride in the presence of coupling agents such as dicyclohexylcarbodiimide and 1-hydroxybenzotriazole in the presence of a base such as diisopropylethylamine. The α-N-carbamoyl protecting group is removed from the resulting peptide-resin using a reagent such as trifluoroacetic acid or piperidine, and the coupling reaction repeated with the next desired N-protected amino acid to be added to the peptide chain. Suitable N-protecting groups are well known in the art, with t-butyloxycarbonyl (tBoc) and fluorenylmethoxycarbonyl (Fmoc) being preferred herein. 
         [0070]    The solvents, amino acid derivatives and 4-methylbenzhydryl-amine resin used in the peptide synthesizer may be purchased from Applied Biosystems Inc. (Foster City, Calif.). The following side-chain protected amino acids may be purchased from Applied Biosystems, Inc.: Boc-Arg(Mts), Fmoc-Arg(Pmc), Boc-Thr(Bzl), Fmoc-Thr(t-Bu), Boc-Ser(Bzl), Fmoc-Ser(t-Bu), Boc-Tyr(BrZ), Fmoc-Tyr(t-Bu), Boc-Lys(Cl-Z), Fmoc-Lys(Boc), Boc-Glu(Bzl), Fmoc-Glu(t-Bu), Fmoc-His(Trt), Fmoc-Asn(Trt), and Fmoc-Gln(Trt). Boc-His(BOM) may be purchased from Applied Biosystems, Inc. or Bachem Inc. (Torrance, Calif.). Anisole, dimethylsulfide, phenol, ethanedithiol, and thioanisole may be obtained from Aldrich Chemical Company (Milwaukee, Wis.). Air Products and Chemicals (Allentown, Pa.) supplies HF. Ethyl ether, acetic acid and methanol may be purchased from Fisher Scientific (Pittsburgh, Pa.). 
         [0071]    Solid phase peptide synthesis may be carried out with an automatic peptide synthesizer (Model 430A, Applied Biosystems Inc., Foster City, Calif.) using the NMP/HOBt (Option 1) system and tBoc or Fmoc chemistry (see, Applied Biosystems User&#39;s Manual for the ABI 430A Peptide Synthesizer, Version 1.3B Jul. 1, 1988, section 6, pp. 49-70, Applied Biosystems, Inc., Foster City, Calif.) with capping. Boc-peptide-resins may be cleaved with HF (−5° C. to 0° C., 1 hour). The peptide may be extracted from the resin with alternating water and acetic acid, and the filtrates lyophilized. The Fmoc-peptide resins may be cleaved according to standard methods (Introduction to Cleavage Techniques, Applied Biosystems, Inc., 1990, pp. 6-12). Peptides may be also be assembled using an Advanced Chem Tech Synthesizer (Model MPS 350, Louisville, Ky.). 
         [0072]    Peptides may be purified by RP-HPLC (preparative and analytical) using a Waters Delta Prep 3000 system. A C4, C8 or C18 preparative column (10μ, 2.2×25 cm; Vydac, Hesperia, Calif.) may be used to isolate peptides, and purity may be determined using a C4, C8 or C18 analytical column (5μ, 0.46×25 cm; Vydac). Solvents (A=0.1% TFA/water and B=0.1% TFA/CH 3 CN) may be delivered to the analytical column at a flowrate of 1.0 ml/min and to the preparative column at 15 ml/min. Amino acid analyses may be performed on the Waters Pico Tag system and processed using the Maxima program. Peptides may be hydrolyzed by vapor-phase acid hydrolysis (115° C., 20-24 h). Hydrolysates may be derivatized and analyzed by standard methods (Cohen, et al., The Pico Tag Method: A Manual of Advanced Techniques for Amino Acid Analysis, pp. 11-52, Millipore Corporation, Milford, Mass. (1989)). Fast atom bombardment analysis may be carried out by M-Scan, Incorporated (West Chester, Pa.). Mass calibration may be performed using cesium iodide or cesium iodide/glycerol. Plasma desorption ionization analysis using time of flight detection may be carried out on an Applied Biosystems Bio-Ion 20 mass spectrometer. Electrospray mass spectroscopy may be carried out on a VG-Trio machine. 
         [0073]    Peptide compounds useful in the invention may also be prepared using recombinant DNA techniques, using methods now known in the art. See, e.g., Sambrook et al., M OLECULAR  C LONING : A L ABORATORY  M ANUAL , 2d Ed., Cold Spring Harbor (1989). Non-peptide compounds useful in the present invention may be prepared by art-known methods. For example, phosphate-containing amino acids and peptides containing such amino acids, may be prepared using methods known in the art. See, e.g., Bartlett and Landen,  Biorg. Chem.  14:356-377 (1986). 
         [0074]    The compounds described above are useful in view of their pharmacological properties. In particular, the compounds of the invention possess activity as agents to reduce food intake. They can be used to treat conditions or diseases which can be alleviated by reducing food intake. 
         [0075]    Compositions useful in the invention may conveniently be provided in the form of formulations suitable for parenteral (including intravenous, intramuscular and subcutaneous) or nasal or oral administration. In some cases, it will be convenient to provide an exendin or exendin agonist and another food-intake-reducing, plasma glucose-lowering or plasma lipid-lowering agent, such as amylin, an amylin agonist, a CCK, or a leptin, in a single composition or solution for administration together. In other cases, it may be more advantageous to administer the additional agent separately from said exendin or exendin agonist. A suitable administration format may best be determined by a medical practitioner for each patient individually. Suitable pharmaceutically acceptable carriers and their formulation are described in standard formulation treatises, e.g., R EMINGTON&#39;S  P HARMACEUTICAL  S CIENCES  by E. W. Martin. See also Wang, Y. J. and Hanson, M. A. “Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers,”  Journal of Parenteral Science and Technology , Technical Report No. 10, Supp. 42:2S (1988). 
         [0076]    Compounds useful in the invention can be provided as parenteral compositions for injection or infusion. They can, for example, be suspended in an inert oil, suitably a vegetable oil such as sesame, peanut, olive oil, or other acceptable carrier. Preferably, they are suspended in an aqueous carrier, for example, in an isotonic buffer solution at a pH of about 3.0 to 8.0, preferably at a pH of about 3.5 to 5.0. These compositions may be sterilized by conventional sterilization techniques, or may be sterile filtered. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH buffering agents. Useful buffers include for example, sodium acetate/acetic acid buffers. A form of repository or “depot” slow release preparation may be used so that therapeutically effective amounts of the preparation are delivered into the bloodstream over many hours or days following transdermal injection or delivery. 
         [0077]    The desired isotonicity may be accomplished using sodium chloride or other pharmaceutically acceptable agents such as dextrose, boric acid, sodium tartrate, propylene glycol, polyols (such as mannitol and sorbitol), or other inorganic or organic solutes. Sodium chloride is preferred particularly for buffers containing sodium ions. 
         [0078]    The claimed compositions can also be formulated as pharmaceutically acceptable salts (e.g., acid addition salts) and/or complexes thereof. Pharmaceutically acceptable salts are non-toxic salts at the concentration at which they are administered. The preparation of such salts can facilitate the pharmacological use by altering the physical-chemical characteristics of the composition without preventing the composition from exerting its physiological effect. Examples of useful alterations in physical properties include lowering the melting point to facilitate transmucosal administration and increasing the solubility to facilitate the administration of higher concentrations of the drug. 
         [0079]    Pharmaceutically acceptable salts include acid addition salts such as those containing sulfate, hydrochloride, phosphate, sulfamate, acetate, citrate, lactate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, cyclohexylsulfamate and quinate. Pharmaceutically acceptable salts can be obtained from acids such as hydrochloric acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, and quinic acid. Such salts may be prepared by, for example, reacting the free acid or base forms of the product with one or more equivalents of the appropriate base or acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is then removed in vacuo or by freeze-drying or by exchanging the ions of an existing salt for another ion on a suitable ion exchange resin. 
         [0080]    Carriers or excipients can also be used to facilitate administration of the compound. Examples of carriers and excipients include calcium carbonate, calcium phosphate, various sugars such as lactose, glucose, or sucrose, or types of starch, cellulose derivatives, gelatin, vegetable oils, polyethylene glycols and physiologically compatible solvents. The compositions or pharmaceutical composition can be administered by different routes including intravenously, intraperitoneal, subcutaneous, and intramuscular, orally, topically, transmucosally, or by pulmonary inhalation. 
         [0081]    If desired, solutions of the above compositions may be thickened with a thickening agent such as methyl cellulose. They may be prepared in emulsified form, either water in oil or oil in water. Any of a wide variety of pharmaceutically acceptable emulsifying agents may be employed including, for example, acacia powder, a non-ionic surfactant (such as a Tween), or an ionic surfactant (such as alkali polyether alcohol sulfates or sulfonates, e.g., a Triton). 
         [0082]    Compositions useful in the invention are prepared by mixing the ingredients following generally accepted procedures. For example, the selected components may be simply mixed in a blender or other standard device to produce a concentrated mixture which may then be adjusted to the final concentration and viscosity by the addition of water or thickening agent and possibly a buffer to control pH or an additional solute to control tonicity. 
         [0083]    For use by the physician, the compositions will be provided in dosage unit form containing an amount of an exendin or exendin agonist, for example, exendin-3, and/or exendin-4, with or without another food intake-reducing, plasma glucose-lowering or plasma lipid-lowering agent. Therapeutically effective amounts of an exendin or exendin agonist for use in reducing food intake are those that suppress appetite at a desired level. As will be recognized by those in the field, an effective amount of therapeutic agent will vary with many factors including the age and weight of the patient, the patient&#39;s physical condition, the blood sugar level and other factors. 
         [0084]    The effective daily appetite-suppressing dose of the compounds will typically be in the range of about 10 to 30 μg to about 5 mg/day, preferably about 10 to 30 μg to about 2 mg/day and more preferably about 10 to 100 μg to about 1 mg/day, most preferably about 30 μg to about 500 μg/day, for a 70 kg patient, administered in a single or divided doses. The exact dose to be administered is determined by the attending clinician and is dependent upon where the particular compound lies within the above quoted range, as well as upon the age, weight and condition of the individual. Administration should begin whenever the suppression of food intake, or weight lowering is desired, for example, at the first sign of symptoms or shortly after diagnosis of obesity, diabetes mellitus, or insulin-resistance syndrome. Administration may be by injection, preferably subcutaneous or intramuscular. Orally active compounds may be taken orally, however dosages should be increased 5-10 fold. 
         [0085]    The optimal formulation and mode of administration of compounds of the present application to a patient depend on factors known in the art such as the particular disease or disorder, the desired effect, and the type of patient. While the compounds will typically be used to treat human subjects they may also be used to treat similar or identical diseases in other vertebrates such as other primates, farm animals such as swine, cattle and poultry, and sports animals and pets such as horses, dogs and cats. 
         [0086]    To assist in understanding the present invention, the following Examples are included. The experiments relating to this invention should not, of course, be construed as specifically limiting the invention and such variations of the invention, now known or later developed, which would be within the purview of one skilled in the art are considered to fall within the scope of the invention as described herein and hereinafter claimed. 
       EXAMPLE 1 
     Exendin Injections Reduced the Food Intake of Normal Mice 
       [0087]    All mice (NIH: Swiss mice) were housed in a stable environment of 22(±2)° C., 60(±10) % humidity and a 12:12 light:dark cycle; with lights on at 0600. Mice were housed in groups of four in standard cages with ad libitum access to food (Teklad: LM 485; Madison, Wis.) and water except as noted, for at least two weeks before the experiments. 
         [0088]    All experiments were conducted between the hours of 0700 and 0900. The mice were food deprived (food removed at 1600 hr from all animals on day prior to experiment) and individually housed. All mice received an intraperitoneal injection (5 μl/kg) of either saline or exendin-4 at doses of 0.1, 1.0, 10 and 100 μg/kg and were immediately presented with a pre-weighed food pellet (Teklad LM 485). The food pellet was weighed at 30-minute, 1-hr, 2-hr and 6-hr intervals to determine the amount of food eaten. 
         [0089]      FIG. 1  depicts cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH: Swiss mice following ip injection of saline, 2 doses of GLP-1, or 4 doses of exendin-4. At doses up to 100 μg/kg, GLP-1 had no effect on food intake measured over any period, a result consistent with that previously reported (Bhavsar, S. P., et al.,  Soc. Neurosci . Abstr. 21:460 (188.8) (1995); and Turton, M. D.,  Nature,  379:69-72, (1996)). 
         [0090]    In contrast, exendin-4 injections potently and dose-dependently inhibited food intake. The ED 50  for inhibition of food intake over 30 min was 1 μg/kg, which is a level about as potent as amylin (ED 50  3.6 μg/kg) or the prototypical peripheral satiety agent, CCK (ED 50  0.97 μg/kg) as measured in this preparation. However, in contrast to the effects of amylin or CCK, which abate after 1-2 hours, the inhibition of food intake with exendin-4 was still present after at least 6 hours after injection. 
       EXAMPLE 2 
     Exendin Reduced the Food Intake of Obese Mice 
       [0091]    All mice (female ob/ob mice) were housed in a stable environment of 22(±2)° C., 60(±10) % humidity and a 12:12 light:dark cycle; with lights on at 0600. Mice were housed in groups of four in standard cages with ad libitum access to food (Teklad: LM 485) and water except as noted, for at least two weeks before the experiments. 
         [0092]    All experiments were conducted between the hours of 0700 and 0900. The mice were food deprived (food removed at 1600 hr from all animals on day prior to experiment) and individually housed. All mice received an intraperitoneal injection (5 μl/kg) of either saline or exendin-4 at doses of 0.1, 1.0 and 10 μg/kg (female ob/ob mice) and were immediately presented with a pre-weighed food pellet (Teklad LM 485). The food pellet was weighed at 30-minute, 1-hr, 2-hr and 6-hr intervals to determine the amount of food eaten. 
         [0093]      FIG. 2  depicts the effect of exendin-4 in the ob/ob mouse model of obesity. The obese mice had a similar food intake-related response to exendin as the normal mice. Moreover, the obese mice were not hypersensitive to exendin, as has been observed with amylin and leptin (Young, A. A., et al., Program and Abstracts, 10th I NTERNATIONAL  C ONGRESS OF  E NDOCRINOLOGY , Jun. 12-15, 1996 San Francisco, pg 419 (P2-58)). 
       EXAMPLE 3 
     Intracerebroventricular Injections of Exendin Inhibited Food Intake in Rats 
       [0094]    All rats (Harlan Sprague-Dawley) were housed in a stable environment of 22(±2)° C., 60(±10) % humidity and a 12:12 light:dark cycle; with lights on at 0600. Rats were obtained from Zivic Miller with an intracerebroventricular cannula (ICV cannula) implanted (coordinates determined by actual weight of animals and referenced to Paxinos, G. and Watson, C. T HE  R AT  B RAIN IN  S TEREOTAXIC  C OORDINATES  2nd ed. Academic Press) and were individually housed in standard cages with ad libitum access to food (Teklad: LM 485) and water for at least one week before the experiments. 
         [0095]    All injections were given between the hours of 1700 and 1800. The rats were habituated to the ICV injection procedure at least once before the ICV administration of compound. All rats received an ICV injection (2 μl/30 seconds) of either saline or exendin-4 at doses of 0.01, 0.03, 0.1, 0.3, and 1.0 μg. All animals were then presented with pre-weighed food (Teklad LM 485) at 1800, when the lights were turned off. The amount of food left was weighed at 2-hr, 12-hr and 24-hr intervals to determine the amount of food eaten by each animal. 
         [0096]      FIG. 3  depicts a dose-dependent inhibition of food intake in rats that received doses greater than 0.1 μg/rat. The ED 50  was ˜0.0.1 μg, exendin-4 is thus ˜100-fold more potent than intracerebroventricular injections of GLP-1 as reported by Turton, M. D., et al. ( Nature  379:69-72 (1996)). 
       EXAMPLE 4 
     Exendin Agonists Reduced the Food Intake in Mice 
       [0097]    All mice (NIH: Swiss mice) were housed in a stable environment of 22 (±2)° C., 60(±10) % humidity and a 12:12 light:dark cycle; with lights on at 0600. Mice were housed in groups of four in standard cages with ad libitum access to food (Teklad: LM 485; Madison, Wis.) and water except as noted, for at least two weeks before the experiments. 
         [0098]    All experiments were conducted between the hours of 0700 and 0900. The mice were food deprived (food removed at 1600 hr from all animals on day prior to experiment) and individually housed. All mice received an intraperitoneal injection (5 μl/kg) of either saline or test compound at doses of 1, 10, and 100 μg/kg and immediately presented with a food pellet (Teklad LM 485). The food pellet was weighed at 30-minute, 1-hr, 2-hr and 6-hr intervals to determine the amount of food eaten. 
         [0099]      FIG. 4  depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH: Swiss mice following ip injection of saline or exendin-4 (1-30) (“Compound 1”) in doses of 1, 10 and 100 μg/kg. 
         [0100]      FIG. 5  depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH: Swiss mice following ip injection of saline or exendin-4 (1-30) amide (“Compound 2”) in doses of 1, 10 and 100 μg/kg. 
         [0101]      FIG. 6  depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH: Swiss mice following ip injection of saline or exendin-4 (1-28) amide (“Compound 3”) in doses of 1, 10 and 100 μg/kg. 
         [0102]      FIG. 7  depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH: Swiss mice following ip injection of saline or  14 Leu,  25 Phe exendin-4 (1-28) amide (“Compound 5”) in doses of 1, 10 and 100 μg/kg. 
         [0103]      FIG. 8  depicts the cumulative food intake over periods of 0.5, 1, 2 and 6 hr in overnight-fasted normal NIH: Swiss mice following ip injection of saline or  14 Leu,  22 Ala,  25 Phe exendin-4 (1-28) amide (“Compound 6”) in doses of 1, 10 and 100 μg/kg. 
       EXAMPLE 5 
     Preparation of Amidated Peptide Having SEQ ID NO: 9 
       [0104]    The above-identified peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA-resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.). In general, single-coupling cycles were used throughout the synthesis and Fast Moc (HBTU activation) chemistry was employed. However, at some positions coupling was less efficient than expected and double couplings were required. In particular, residues Asp 9 , Thr 7  and Phe 6  all required double coupling. Deprotection (Fmoc group removal) of the growing peptide chain using piperidine was not always efficient. Double deprotection was required at positions Arg 20 , Val 19  and Leu 14 . Final deprotection of the completed peptide resin was achieved using a mixture of triethylsilane (0.2 mL), ethanedithiol (0.2 mL), anisole (0.2 mL), water (0.2 mL) and trifluoroacetic acid (15 mL) according to standard methods (Introduction to Cleavage Techniques, Applied Biosystems, Inc.) The peptide was precipitated in ether/water (50 mL) and centrifuged. The precipitate was reconstituted in glacial acetic acid and lyophilized. The lyophilized peptide was dissolved in water). Crude purity was about 55%. 
         [0105]    Used in purification steps and analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). 
         [0106]    The solution containing peptide was applied to a preparative C-18 column and purified (10% to 40% Solvent B in Solvent A over 40 minutes). Purity of fractions was determined isocratically using a C-18 analytical column. Pure fractions were pooled furnishing the above-identified peptide. Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.5 minutes. Electrospray Mass Spectrometry (M): calculated 4131.7; found 4129.3. 
       EXAMPLE 6 
     Preparation of Peptide Having SEQ ID NO: 10 
       [0107]    The above-identified peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 25% to 75% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 21.5 minutes. Electrospray Mass Spectrometry (M): calculated 4168.6; found 4171.2. 
       EXAMPLE 7 
     Preparation of Peptide Having SEQ ID NO: 11 
       [0108]    The above-identified peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 17.9 minutes. Electrospray Mass Spectrometry (M): calculated 4147.6; found 4150.2. 
       EXAMPLE 8 
     Preparation of Peptide Having SEQ ID NO: 12 
       [0109]    The above-identified peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 35% to 65% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 19.7 minutes. Electrospray Mass Spectrometry (M): calculated 4212.6; found 4213.2. 
       EXAMPLE 9 
     Preparation of Peptide Having SEQ ID NO: 13 
       [0110]    The above-identified peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 50% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 16.3 minutes. Electrospray Mass Spectrometry (M): calculated 4262.7; found 4262.4. 
       EXAMPLE 10 
     Preparation of Peptide Having SEQ ID NO: 14 
       [0111]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4172.6 
       EXAMPLE 11 
     Preparation of Peptide Having SEQ ID NO: 15 
       [0112]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4224.7. 
       EXAMPLE 12 
     Preparation of Peptide Having SEQ ID NO: 16 
       [0113]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4172.6 
       EXAMPLE 13 
     Preparation of Peptide Having SEQ ID NO: 17 
       [0114]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4186.6 
       EXAMPLE 14 
     Preparation of Peptide Having SEQ ID NO: 18 
       [0115]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4200.7 
       EXAMPLE 15 
     Preparation of Peptide Having SEQ ID NO: 19 
       [0116]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4200.7 
       EXAMPLE 16 
     Preparation of Peptide Having SEQ ID NO: 20 
       [0117]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4202.7. 
       EXAMPLE 17 
     Preparation of Peptide Having SEQ ID NO: 21 
       [0118]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4145.6. 
       EXAMPLE 18 
     Preparation of Peptide Having SEQ ID NO: 22 
       [0119]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4184.6. 
       EXAMPLE 19 
     Preparation of Peptide Having SEQ ID NO: 23 
       [0120]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4145.6. 
       EXAMPLE 20 
     Preparation of Peptide Having SEQ ID NO: 24 
       [0121]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4224.7. 
       EXAMPLE 21 
     Preparation of Peptide Having SEQ ID NO: 25 
       [0122]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4172.6. 
       EXAMPLE 22 
     Preparation of Peptide Having SEQ ID NO: 26 
       [0123]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4115.5. 
       EXAMPLE 23 
     Preparation of Peptide Having SEQ ID NO: 27 
       [0124]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4188.6. 
       EXAMPLE 24 
     Preparation of Peptide Having SEQ ID NO: 28 
       [0125]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4131.6. 
       EXAMPLE 25 
     Preparation of Peptide Having SEQ ID NO: 29 
       [0126]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4172.6. 
       EXAMPLE 26 
     Preparation of Peptide Having SEQ ID NO: 30 
       [0127]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4145.6. 
       EXAMPLE 27 
     Preparation of Peptide Having SEQ ID NO: 31 
       [0128]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the thioproline positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4266.8. 
       EXAMPLE 28 
     Preparation of Peptide Having SEQ ID NO: 32 
       [0129]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the thioproline positions 38, 37 and 36. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4246.8. 
       EXAMPLE 29 
     Preparation of Peptide Having SEQ ID NO: 33 
       [0130]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the homoproline positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4250.8. 
       EXAMPLE 30 
     Preparation of Peptide Having SEQ ID NO: 34 
       [0131]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the homoproline positions 38, 37, and 36. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4234.8. 
       EXAMPLE 31 
     Preparation of Peptide Having SEQ ID NO: 35 
       [0132]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the thioproline positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4209.8. 
       EXAMPLE 32 
     Preparation of Peptide Having SEQ ID NO: 36 
       [0133]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the homoproline positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4193.7. 
       EXAMPLE 33 
     Preparation of Peptide Having SEQ ID NO: 37 
       [0134]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the N-methylalanine positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3858.2. 
       EXAMPLE 34 
     Preparation of Peptide Having SEQ ID NO: 38 
       [0135]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the N-methylalanine positions 38, 37 and 36. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3940.3. 
       EXAMPLE 35 
     Preparation of Peptide Having SEQ ID NO: 39 
       [0136]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Additional double couplings are required at the N-methylalanine positions 38, 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3801.1. 
       EXAMPLE 36 
     Preparation of C-Terminal Carboxylic Acid Peptides Corresponding to the Above C-Terminal Amide Sequences 
       [0137]    The above peptides of Examples 5 to 35 are assembled on the so called Wang resin (p-alkoxybenzylalacohol resin (Bachem, 0.54 mmole/g)) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 5. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry provides an experimentally determined (M). 
       EXAMPLE 37 
     Preparation of Peptide Having SEQ ID NO:7 
       [0138]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 7] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys 
                   
               
               
                   
               
               
                 Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu 
               
               
                   
               
               
                 Trp Leu Lys Asn Gly Gly-NH 2   
               
             
          
         
       
     
         [0139]    The above amidated peptide was assembled on 4-(2′-4′-dimethoxypheny-1)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.). In general, single-coupling cycles were used throughout the synthesis and Fast Moc (HBTU activation) chemistry was employed. Deprotection (Fmoc group removal) of the growing peptide chain was achieved using piperidine. Final deprotection of the completed peptide resin was achieved using a mixture of triethylsilane (0.2 mL), ethanedithiol (0.2 mL), anisole (0.2 mL), water (0.2 mL) and trifluoroacetic acid (15 mL) according to standard methods (Introduction to Cleavage Techniques, Applied Biosystems, Inc.) The peptide was precipitated in ether/water (50 mL) and centrifuged. The precipitate was reconstituted in glacial acetic acid and lyophilized. The lyophilized peptide was dissolved in water). Crude purity was about 75%. 
         [0140]    Used in purification steps and analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). The solution containing peptide was applied to a preparative C-18 column and purified (10% to 40% Solvent B in Solvent A over 40 minutes). Purity of fractions was determined isocratically using a C-18 analytical column. Pure fractions were pooled furnishing the above-identified peptide. Analytical RP-HPLC (gradient 30% to 50% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 18.9 minutes. Electrospray Mass Spectrometry (M): calculated 3408.0; found 3408.9. 
       EXAMPLE 38 
     Preparation of Peptide Having SEQ ID NO:40 
       [0141]      
         [0000]    
       
         
               
             
               
             
           
               
                 [SEQ ID NO: 40] 
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys 
               
               
                   
               
               
                 Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu 
               
               
                   
               
               
                 Trp Leu Lye Asn-NH 2   
               
             
          
         
       
     
         [0142]    The above amidated peptide was assembled on 4-(2′-4′-dimethoxypheny-1)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 40% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 17.9 minutes. Electrospray Mass Spectrometry (M) calculated 3294.7; found 3294.8. 
       EXAMPLE 39 
     Preparation of Peptide Having SEQ ID NO:41 
       [0143]      
         [0000]    
       
         
               
             
               
             
           
               
                 [SEQ ID NO: 41] 
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys 
               
               
                   
               
               
                 Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu 
               
               
                   
               
               
                 Phe Leu Lys Asn-NH 2   
               
             
          
         
       
     
         [0144]    The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 29% to 36% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of. 20.7 minutes. Electrospray Mass Spectrometry (M): calculated 3237.6; found 3240. 
       EXAMPLE 40 
     Preparation of Peptide Having SEQ ID NO:42 
       [0145]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:42] 
                   
               
             
          
           
               
                 His Ala Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0146]    The above amidated peptide was assembled on 4-(2.1-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 36% to 46% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 15.2 minutes. Electrospray Mass Spectrometry (M): calculated 3251.6; found 3251.5. 
       EXAMPLE 41 
     Preparation of Peptide Having SEQ ID NO:43 
       [0147]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:43] 
                   
               
             
          
           
               
                 His Gly Glu Gly Ala Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0148]    The above amidated peptide was assembled on 4-(2′-4′-dimethoxypheny-1)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 36% to 46% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 13.1 minutes. Electrospray Mass Spectrometry (M): calculated 3207.6; found 3208.3. 
       EXAMPLE 42 
     Preparation of Peptide Having SEQ ID NO: 44 
       [0149]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:44] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Ala Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0150]    The above amidated peptide was assembled on 4-(2′-4′-dimethoxypheny-1)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 35% to 45% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 12.8 minutes. Electrospray Mass Spectrometry (M): calculated 3161.5; found 3163. 
       EXAMPLE 43 
     Preparation of Peptide Having SEQ ID NO: 45 
       [0151]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:45] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ala Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0152]    The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 36% to 46% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 15.2 minutes. Electrospray Mass Spectrometry (M): calculated 3221.6; found 3222.7. 
       EXAMPLE 44 
     Preparation of Peptide Having SEQ ID NO:46 
       [0153]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:46] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0154]    The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 34% to 44% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.3 minutes. Electrospray Mass Spectrometry (M): calculated 3195.5; found 3199.4. 
       EXAMPLE 45 
     Preparation of Peptide Having SEQ ID NO: 47 
       [0155]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:47] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ala Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0156]    The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 38% to 48% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 15.7 minutes. Electrospray Mass Spectrometry (M): calculated 3221.6; found 3221.6. 
       EXAMPLE 46 
     Preparation of Peptide Having SEQ ID NO: 48 
       [0157]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:48] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Ala Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0158]    The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent. B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 38% to 48% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 18.1 minutes. Electrospray Mass Spectrometry (M): calculated 3180.5; found 3180.9. 
       EXAMPLE 47 
     Preparation of Peptide Having SEQ ID NO: 49 
       [0159]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:49] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Ala 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0160]    The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Compound 1. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 36% to 46% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 17.0 minutes. Electrospray Mass Spectrometry (M): calculated 3180.6; found 3182.8. 
       EXAMPLE 48 
     Preparation of Peptide Having SEQ ID NO: 50 
       [0161]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:50] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Ala Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0162]    The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 32% to 42% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.9 minutes. Electrospray Mass Spectrometry (M): calculated 3195.5; found 3195.9. 
       EXAMPLE 49 
     Preparation of Peptide Having SEQ ID NO: 51 
       [0163]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:51] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Ala Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0164]    The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical. RP-HPLC (gradient 37% to 47% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 17.9 minutes. Electrospray Mass Spectrometry (M): calculated 3179.6; found 3179.0. 
       EXAMPLE 50 
     Preparation of Peptide Having SEQ ID NO: 52 
       [0165]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:52] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Ala Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0166]    The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 37% to 47% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.3 minutes. Electrospray Mass Spectrometry (M): calculated 3179.6; found 3180.0. 
       EXAMPLE 51 
     Preparation of Peptide Having SEQ ID NO: 53 
       [0167]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:53] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Ala Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0168]    The above-identified peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 37% to 47% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 13.7 minutes. Electrospray Mass Spectrometry (M): calculated 3179.6; found 3179.0. 
       EXAMPLE 52 
     Preparation of Peptide Having SEQ ID NO: 54 
       [0169]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:54] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Ala Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0170]    The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 35% to 45% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.0 minutes. Electrospray Mass Spectrometry (M): calculated 3209.6; found 3212.8. 
       EXAMPLE 53 
     Preparation of Peptide Having SEQ ID NO: 55 
       [0171]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:55] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Ala Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0172]    The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 38% to 48% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.3 minutes. Electrospray Mass Spectrometry (M): calculated 3152.5; found 3153.5. 
       EXAMPLE 54 
     Preparation of Peptide Having SEQ ID NO: 56 
       [0173]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:56] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Ala Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0174]    The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 35% to 45% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 12.1 minutes. Electrospray Mass Spectrometry (M): calculated 3195.5; found 3197.7. 
       EXAMPLE 55 
     Preparation of Peptide Having SEQ ID NO: 57 
       [0175]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:57] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Ala Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0176]    The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 38% to 48% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 10.9 minutes. Electrospray Mass Spectrometry (M): calculated 3179.6; found 3180.5. 
       EXAMPLE 56 
     Preparation of Peptide Having SEQ ID NO: 58 
       [0177]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:58] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Ala Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0178]    The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 32% to 42% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 17.5 minutes. Electrospray Mass Spectrometry (M): calculated 3161.5; found 3163.0. 
       EXAMPLE 57 
     Preparation of Peptide Having SEQ ID NO: 59 
       [0179]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:59] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Ala 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0180]    The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 32% to 42% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 19.5 minutes. Electrospray Mass Spectrometry (M): calculated 3195.5; found 3199. 
       EXAMPLE 58 
     Preparation of Peptide Having SEQ ID NO: 60 
       [0181]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:60] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Ala Asn-NH 2   
               
             
          
         
       
     
         [0182]    The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 38% to 48% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.5 minutes. Electrospray Mass Spectrometry (M): calculated 3180.5; found 3183.7. 
       EXAMPLE 59 
     Preparation of Peptide Having SEQ ID NO: 61 
       [0183]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:61] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Ala-NH 2   
               
             
          
         
       
     
         [0184]    The above-identified amidated peptide was assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 34% to 44% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 22.8 minutes. Electrospray Mass Spectrometry (M): calculated 3194.6; found 3197.6. 
       EXAMPLE 60 
     Preparation of Peptide Having SEQ ID NO: 62 
       [0185]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:62] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro-NH 2   
               
             
          
         
       
     
         [0186]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4099.6. 
       EXAMPLE 61 
     Preparation of Peptide Having SEQ ID NO: 63 
       [0187]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:63] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro-NH 2   
               
             
          
         
       
     
         [0188]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4042.5. 
       EXAMPLE 62 
     Preparation of Peptide Having SEQ ID NO: 64 
       [0189]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:64] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro-NH 2   
               
             
          
         
       
     
         [0190]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4002.4 
       EXAMPLE 63 
     Preparation of Peptide Having SEQ ID NO: 65 
       [0191]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:65] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro-NH 2   
               
             
          
         
       
     
         [0192]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3945.4. 
       EXAMPLE 64 
     Preparation of Peptide Having SEQ ID NO: 66 
       [0193]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:66] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Val Arg Leu Phe Ile Glu 
               
               
                   
               
               
                 Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro-NH 2   
               
             
          
         
       
     
         [0194]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3905.3. 
       EXAMPLE 65 
     Preparation of Peptide Having SEQ ID NO: 67 
       [0195]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:67] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro-NH 2   
               
             
          
         
       
     
         [0196]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3848.2. 
       EXAMPLE 66 
     Preparation of Peptide Having SEQ ID NO: 68 
       [0197]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:68] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser Ser Gly Ala-NH 2   
               
             
          
         
       
     
         [0198]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3808.2. 
       EXAMPLE 67 
     Preparation of Peptide Having SEQ ID NO: 69 
       [0199]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:69] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser Ser Gly Ala-NH 2   
               
             
          
         
       
     
         [0200]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3751.1. 
       EXAMPLE 68 
     Preparation of Peptide Having SEQ ID NO: 70 
       [0201]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:70] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser Ser Gly-NH 2   
               
             
          
         
       
     
         [0202]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3737.1. 
       EXAMPLE 69 
     Preparation of Peptide Having SEQ ID NO: 71 
       [0203]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:71] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser Ser Gly-NH 2   
               
             
          
         
       
     
         [0204]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1%, TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3680.1. 
       EXAMPLE 70 
     Preparation of Peptide Having SEQ ID NO: 72 
       [0205]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:72] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser Ser-NH 2   
               
             
          
         
       
     
         [0206]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 0.30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3680.1 
       EXAMPLE 71 
     Preparation of Peptide Having SEQ ID NO: 73 
       [0207]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:73] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser Ser-NH 2   
               
             
          
         
       
     
         [0208]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3623.0. 
       EXAMPLE 72 
     Preparation of Peptide Having SEQ ID NO: 74 
       [0209]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:74] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser-NH 2   
               
             
          
         
       
     
         [0210]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/q) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3593.0 
       EXAMPLE 73 
     Preparation of Peptide Having SEQ ID NO: 75 
       [0211]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:75] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser-NH 2   
               
             
          
         
       
     
         [0212]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3535.9 
       EXAMPLE 74 
     Preparation of Peptide Having SEQ ID NO: 76 
       [0213]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:76] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro-NH 2   
               
             
          
         
       
     
         [0214]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g): using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 0.60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3505.9. 
       EXAMPLE 75 
     Preparation of Peptide Having SEQ ID NO: 77 
       [0215]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:77] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro-NH 2   
               
             
          
         
       
     
         [0216]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3448.8. 
       EXAMPLE 76 
     Preparation of Peptide Having SEQ ID NO: 78 
       [0217]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:78] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly-NH 2   
               
             
          
         
       
     
         [0218]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3351.7. 
       EXAMPLE 77 
     Preparation of Peptide Having SEQ ID NO: 79 
       [0219]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:79] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly-NH 2   
               
             
          
         
       
     
         [0220]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3351.8. 
       EXAMPLE 78 
     Preparation of Peptide Having SEQ ID NO: 80 
       [0221]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:80] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn Gly-NH 2   
               
             
          
         
       
     
         [0222]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M) calculated 3294.7. 
       EXAMPLE 79 
     Preparation of Peptide Having SEQ ID NO: 81 
       [0223]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:81] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly tPro Ser Ser Gly Ala tPro tPro 
               
               
                   
               
               
                 tPro-NH 2   
               
             
          
         
       
     
         [0224]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Double couplings are required at residues 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4197.1. 
       EXAMPLE 80 
     Preparation of Peptide Having SEQ ID NO: 82 
       [0225]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:82] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser Ser Gly Ala tPro tPro 
               
               
                   
               
               
                 tPro-NH 2   
               
             
          
         
       
     
         [0226]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied. Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Double couplings are required at residues 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4179.1. 
       EXAMPLE 81 
     Preparation of Peptide Having SEQ ID NO: 83 
       [0227]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:83] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly NMeala Ser Ser Gly Ala Pro Pro-NH 2   
               
             
          
         
       
     
         [0228]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Double couplings are required at residues 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3948.3. 
       EXAMPLE 82 
     Preparation of Peptide Having SEQ ID NO: 84 
       [0229]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:84] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly NMeala Ser Ser Gly Ala NMeala 
               
               
                   
               
               
                 Nmeala-NH 2   
               
             
          
         
       
     
         [0230]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Double couplings are required at residues 36 and 31. Used in analysis are Solvent A. (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide, is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3840.1. 
       EXAMPLE 83 
     Preparation of Peptide Having SEQ ID NO: 85 
       [0231]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:85] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly hPro Ser Ser Gly Ala hPro hPro-NH 2   
               
             
          
         
       
     
         [0232]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Double couplings are required at residues 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4050.1. 
       EXAMPLE 84 
     Preparation of Peptide Having SEQ ID NO: 86 
       [0233]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:86] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly hPro Ser Ser Gly Ala hPro-NH 2   
               
             
          
         
       
     
         [0234]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. A double coupling is required at residue 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3937.1 
       EXAMPLE 85 
     Preparation of Peptide Having SEQ ID NO: 87 
       [0235]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 87] 
                   
               
             
          
           
               
                 Arg Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser Ser Gly Ala-NH 2   
               
             
          
         
       
     
         [0236]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3827.2. 
       EXAMPLE 86 
     Preparation of Peptide Having SEQ ID NO: 88 
       [0237]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 88] 
                   
               
             
          
           
               
                 His Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly-NH 2   
               
             
          
         
       
     
         [0238]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3394.8. 
       EXAMPLE 87 
     Preparation of Peptide Having SEQ ID NO: 89 
       [0239]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 89] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Naphthylala Thr Ser Asp Leu Ser 
                   
               
               
                   
               
               
                 Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu 
               
               
                   
               
               
                 Phe Leu Lys Asn-NH 2   
               
             
          
         
       
     
         [0240]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems., Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent. A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention-time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3289.5. 
       EXAMPLE 88 
     Preparation of Peptide Having SEQ ID NO: 90 
       [0241]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 90] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Ser Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0242]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray, Mass Spectrometry (M): calculated 3280.7. 
       EXAMPLE 89 
     Preparation of Peptide Having SEQ ID NO: 91 
       [0243]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 91] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Ser Thr Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Gln Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0244]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3294.7. 
       EXAMPLE 90 
     Preparation of Peptide Having SEQ ID NO: 92 
       [0245]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 92] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Glu Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Ala Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0246]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A. (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3250.7. 
       EXAMPLE 91 
     Preparation of Peptide Having SEQ ID NO: 93 
       [0247]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 93] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp pentylgly Ser 
                   
               
               
                   
               
               
                 Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu 
               
               
                   
               
               
                 Phe Leu Lys Asn-NH 2   
               
             
          
         
       
     
         [0248]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B. (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3253.5. 
       EXAMPLE 92 
     Preparation of Peptide Having SEQ ID NO: 94 
       [0249]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 94] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Naphthylala Ile Glu 
               
               
                   
               
               
                 Phe Leu Lys Asn-NH 2   
               
             
          
         
       
     
         [0250]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3289.5. 
       EXAMPLE 93 
     Preparation of Peptide Having SEQ ID NO: 95 
       [0251]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 95] 
                   
               
             
          
           
               
                 His Guy Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe tButylgly Glu 
               
               
                   
               
               
                 Trp Leu Lys Asn-NH 2   
               
             
          
         
       
     
         [0252]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3183.4. 
       EXAMPLE 94 
     Preparation of Peptide Having SEQ ID NO: 96 
       [0253]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 96] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Asp Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0254]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3237.6. 
       EXAMPLE 95 
     Preparation of Peptide Having SEQ ID NO: 97 
       [0255]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 97] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser Ser-NH 2   
               
             
          
         
       
     
         [0256]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3637.9. 
       EXAMPLE 96 
     Preparation of Peptide Having SEQ ID NO: 98 
       [0257]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 98] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly-NH 2   
               
             
          
         
       
     
         [0258]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3309.7. 
       EXAMPLE 97 
     Preparation of Peptide Having SEQ ID NO: 99 
       [0259]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 99] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly hPro Ser Ser Gly Ala hPro hPro-NH 2   
               
             
          
         
       
     
         [0260]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Double couplings are required at residues 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3711.1. 
       EXAMPLE 98 
     Preparation of C-Terminal Carboxylic Acid Peptides Corresponding to the C-Terminal Amide Sequences for SEQ ID NOs. 7, 40-61, 68-75, 78-80 and 87-96 
       [0261]    Peptides having the sequences of SEQ ID NOs. 7, 40-61, 68-75, 78-80 and 87-96 are assembled on the so called Wang resin (p-alkoxybenzylalacohol resin (Bachem, 0.54 mmole/g)) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry provides an experimentally determined (M). 
       EXAMPLE 99 
     Preparation of C-Terminal Carboxylic Acid Peptides Corresponding to the Above C-Terminal Amide Sequences for SEQ ID NOs. 62-67, 76, 77 and 81-86 
       [0262]    Peptides having the sequences of SEQ ID NOs. 62-67, 76, 77 and 81-86 are assembled on the 2-chlorotritylchloride resin (200-400 mesh), 2% DVB (Novabiochem, 0.4-1.0 mmole/g)) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 37. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry provides an experimentally determined (M). 
       EXAMPLE 100 
     Preparation of Peptide Having SEQ ID NO: 100 
       [0263]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 100] 
                   
               
             
          
           
               
                 Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0264]    The above amidated peptide was assembled on 4-(2′-4′-dimethoxypheny-1)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.). In general, single-coupling cycles were used throughout the synthesis and Fast Moc (HBTU activation) chemistry was employed. Deprotection (Fmoc group removal) of the growing peptide chain was achieved using piperidine. Final deprotection of the completed peptide resin was achieved using a mixture of triethylsilane (0.2 mL), ethanedithiol (0.2 mL), anisole (0.2 mL), water (0.2 mL) and trifluoroacetic acid (15 mL) according to standard methods (Introduction to Cleavage Techniques, Applied Biosystems, Inc.) The peptide was precipitated in ether/water (50 mL) and centrifuged. The precipitate was reconstituted in glacial acetic acid and lyophilized. The lyophilized peptide was dissolved in water). Crude purity was about 75%. 
         [0265]    Used in purification steps and analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). The solution containing peptide was applied to a preparative C-18 column and purified (10% to 40% Solvent B in Solvent A over 40 minutes). Purity of fractions was determined isocratically using a C-18 analytical column. Pure fractions were pooled furnishing the above-identified peptide. Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 19.2 minutes. Electrospray Mass Spectrometry (M): calculated 3171.6; found 3172. 
       EXAMPLE 101 
     Preparation of Peptide Having SEQ ID NO: 101 
       [0266]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 101] 
                   
               
             
          
           
               
                 His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0267]    The above amidated peptide was assembled on 4-(2′-4′-dimethoxypheny-1)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 36% to 46% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 14.9 minutes. Electrospray Mass Spectrometry (M): calculated 3179.6; found 3180. 
       EXAMPLE 102 
     Preparation of Peptide Having SEQ ID NO: 102 
       [0268]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:102] 
                   
               
             
          
           
               
                 His Gly Glu Ala Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0269]    The above amidated peptide was assembled on 4-(2′-4′-dimethoxypheny-1)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 37% to 47% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 12.2 minutes. Electrospray Mass Spectrometry (M): calculated 3251.6; found 3253.3. 
       EXAMPLE 103 
     Preparation of Peptide Having SEQ ID NO: 103 
       [0270]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:103] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Ala Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0271]    The above amidated peptide was assembled on 4-(2′-4′-dimethoxypheny-1)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis were Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 35% to 45% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide gave product peptide having an observed retention time of 16.3 minutes. Electrospray Mass Spectrometry (M): calculated 3193.6; found 3197. 
       EXAMPLE 104 
     Preparation of Peptide Having SEQ ID NO: 104 
       [0272]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:104] 
                   
               
             
          
           
               
                 Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0273]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3228.6. 
       EXAMPLE 105 
     Preparation of Peptide Having SEQ ID NO: 105 
       [0274]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:105] 
                   
               
             
          
           
               
                 His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0275]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3234.7. 
       EXAMPLE 106 
     Preparation of Peptide Having SEQ ID NO: 106 
       [0276]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:106] 
                   
               
             
          
           
               
                 His Gly Glu Ala Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0277]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3308.7. 
       EXAMPLE 107 
     Preparation of Peptide Having SEQ ID NO: 107 
       [0278]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:107] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Ala Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0279]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3250.7 
       EXAMPLE 108 
     Preparation of Peptide Having SEQ ID NO: 108 
       [0280]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:108] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0281]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3252.6. 
       EXAMPLE 109 
     Preparation of Peptide Having SEQ ID NO: 109 
       [0282]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:109] 
                   
               
             
          
           
               
                 Ala Ala Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0283]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis ate Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3200.6. 
       EXAMPLE 110 
     Preparation of Peptide Having SEQ ID NO: 110 
       [0284]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:110] 
                   
               
             
          
           
               
                 Ala Ala Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0285]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3143.5. 
       EXAMPLE 111 
     Preparation of Peptide Having SEQ ID NO: 111 
       [0286]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:111] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0287]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3214.6. 
       EXAMPLE 112 
     Preparation of Peptide Having SEQ ID NO: 112 
       [0288]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:112] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0289]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3157.5. 
       EXAMPLE 113 
     Preparation of Peptide Having SEQ ID NO: 113 
       [0290]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:113] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Ala Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0291]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3184.6. 
       EXAMPLE 114 
     Preparation of Peptide Having SEQ ID NO: 114 
       [0292]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:114] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Ala Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0293]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3127.5. 
       EXAMPLE 115 
     Preparation of Peptide Having SEQ ID NO: 115 
       [0294]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:115] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr NaphthylAla Thr Ser Asp Leu Ser 
                   
               
               
                   
               
               
                 Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu 
               
               
                   
               
               
                 Trp Leu Lys Asn-NH 2   
               
             
          
         
       
     
         [0295]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3266.4. 
       EXAMPLE 116 
     Preparation of Peptide Having SEQ ID NO: 116 
       [0296]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:116] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Naphthylala Thr Ser Asp Leu 
                   
               
               
                   
               
               
                 Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile 
               
               
                   
               
               
                 Glu Phe Leu Lys Asn-NH 2   
               
             
          
         
       
     
         [0297]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3209.4. 
       EXAMPLE 117 
     Preparation of Peptide Having SEQ ID NO: 117 
       [0298]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:117] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Ser Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0299]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3200.6. 
       EXAMPLE 118 
     Preparation of Peptide Having SEQ ID NO: 118 
       [0300]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:118] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Ser Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0301]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3143.5. 
       EXAMPLE 119 
     Preparation of Peptide Having SEQ ID NO: 119 
       [0302]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:119] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ala Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0303]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3198.6. 
       EXAMPLE 120 
     Preparation of Peptide Having SEQ ID NO: 120 
       [0304]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:120] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ala Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0305]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3141.5. 
       EXAMPLE 121 
     Preparation of Peptide Having SEQ ID NO: 121 
       [0306]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:121] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Ala Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0307]    The above-identified peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mm ole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3170.6. 
       EXAMPLE 122 
     Preparation of Peptide Having SEQ ID NO: 122 
       [0308]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:122] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Ala Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0309]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are. Solvent A (0.1% TFA in water) and Solvent B. (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3113.5. 
       EXAMPLE 123 
     Preparation of Peptide Having SEQ ID NO: 123 
       [0310]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:123] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Glu Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0311]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3228.6. 
       EXAMPLE 124 
     Preparation of Peptide Having SEQ ID NO: 124 
       [0312]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:124] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Glu Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0313]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3171.6. 
       EXAMPLE 125 
     Preparation of Peptide Having SEQ ID NO: 125 
       [0314]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:125] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0315]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3172.5. 
       EXAMPLE 126 
     Preparation of Peptide Having SEQ ID NO: 126 
       [0316]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:126] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0317]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3115.4. 
       EXAMPLE 127 
     Preparation of Peptide Having SEQ ID NO: 127 
       [0318]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:127] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Pentylgly Ser 
                   
               
               
                   
               
               
                 Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu 
               
               
                   
               
               
                 Trp Leu Lys Asn-NH 2   
               
             
          
         
       
     
         [0319]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3230.4. 
       EXAMPLE 128 
     Preparation of Peptide Having SEQ ID NO: 128 
       [0320]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:128] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Pentylgly Ser 
                   
               
               
                   
               
               
                 Lys Gln Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu 
               
               
                   
               
               
                 Phe Leu Lys Asn-NH 2   
               
             
          
         
       
     
         [0321]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3198.6. 
       EXAMPLE 129 
     Preparation of Peptide Having SEQ ID NO: 129 
       [0322]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:129] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ala Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0323]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3141.5. 
       EXAMPLE 130 
     Preparation of Peptide Having SEQ ID NO: 130 
       [0324]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:130] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ala Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0325]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3157.5. 
       EXAMPLE 131 
     Preparation of Peptide Having SEQ ID NO: 131 
       [0326]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:131] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Ala Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0327]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3100.4. 
       EXAMPLE 132 
     Preparation of Peptide Having SEQ ID NO: 132 
       [0328]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:132] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Ala Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0329]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3157.6. 
       EXAMPLE 133 
     Preparation of Peptide Having SEQ ID NO: 133 
       [0330]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:133] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Ala 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0331]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3100.5. 
       EXAMPLE 134 
     Preparation of Peptide Having SEQ ID NO: 134 
       [0332]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:134] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Ala 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0333]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3100.5. 
       EXAMPLE 135 
     Preparation of Peptide Having SEQ ID NO: 135 
       [0334]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:135] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Ala Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0335]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3154.5. 
       EXAMPLE 136 
     Preparation of Peptide Having SEQ ID NO: 136 
       [0336]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:136] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Ala Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0337]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3115.5. 
       EXAMPLE 137 
     Preparation of Peptide Having SEQ ID NO: 137 
       [0338]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:137] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Pentylgly Glu Glu Glu Ala Val Arg Leu Phe Ile Glu 
               
               
                   
               
               
                 Trp Leu Lys Asn-NH 2   
               
             
          
         
       
     
         [0339]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3212.4. 
       EXAMPLE 138 
     Preparation of Peptide Having SEQ ID NO: 138 
       [0340]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:138] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Pentylgly Glu Glu Glu Ala Val Arg Leu Phe Ile Glu 
               
               
                   
               
               
                 Phe Leu Lys Asn-NH 2   
               
             
          
         
       
     
         [0341]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3173.4. 
       EXAMPLE 139 
     Preparation of Peptide Having SEQ ID NO: 139 
       [0342]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:139] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Ala Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0343]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3156.6. 
       EXAMPLE 140 
     Preparation of Peptide Having SEQ ID NO: 140 
       [0344]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:140] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Ala Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0345]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3099.5. 
       EXAMPLE 141 
     Preparation of Peptide Having SEQ ID NO: 141 
       [0346]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:141] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Ala Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0347]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100′. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3156.6. 
       EXAMPLE 142 
     Preparation of Peptide Having SEQ ID NO: 142 
       [0348]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:142] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Ala Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0349]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B. (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3099.5. 
       EXAMPLE 143 
     Preparation of Peptide Having SEQ ID NO: 143 
       [0350]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:143] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Ala Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0351]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3156.6. 
       EXAMPLE 144 
     Preparation of Peptide Having SEQ ID NO:144 
       [0352]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:144] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Ala Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0353]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3099.5. 
       EXAMPLE 145 
     Preparation of Peptide Having SEQ ID NO: 145 
       [0354]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:145] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Ala Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0355]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3186.6. 
       EXAMPLE 146 
     Preparation of Peptide Having SEQ ID NO: 146 
       [0356]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:146] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Ala Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0357]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3129.5. 
       EXAMPLE 147 
     Preparation of Peptide Having SEQ ID NO: 147 
       [0358]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:147] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Ala Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0359]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3129.5. 
       EXAMPLE 148 
     Preparation of Peptide Having SEQ ID NO: 148 
       [0360]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:148] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Ala Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0361]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3072.4. 
       EXAMPLE 149 
     Preparation of Peptide Having SEQ ID NO: 149 
       [0362]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:149] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Ala Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0363]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3172.5. 
       EXAMPLE 150 
     Preparation of Peptide Having SEQ ID NO: 150 
       [0364]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:150] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Ala Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0365]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3115.5. 
       EXAMPLE 151 
     Preparation of Peptide Having SEQ ID NO: 151 
       [0366]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:151] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Naphthylala Ile Glu 
               
               
                   
               
               
                 Trp Leu Lys Asn-NH 2   
               
             
          
         
       
     
         [0367]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.5.5 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3266.4. 
       EXAMPLE 152 
     Preparation of Peptide Having SEQ ID NO: 152 
       [0368]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:152] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Naphthylala Ile Glu 
               
               
                   
               
               
                 Phe Leu Lys Asn-NH 2   
               
             
          
         
       
     
         [0369]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3209.4. 
       EXAMPLE 153 
     Preparation of Peptide Having SEQ ID NO: 153 
       [0370]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:153] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Val Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0371]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3200.6. 
       EXAMPLE 154 
     Preparation of Peptide Having SEQ ID NO: 154 
       [0372]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:154] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Val Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0373]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3143.5. 
       EXAMPLE 155 
     Preparation of Peptide Having SEQ ID NO: 155 
       [0374]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:155] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe tButylgly Glu 
               
               
                   
               
               
                 Trp Leu Lys Asn-NH 2   
               
             
          
         
       
     
         [0375]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3216.5. 
       EXAMPLE 156 
     Preparation of Peptide Having SEQ ID NO: 156 
       [0376]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:156] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe tButylgly Glu 
               
               
                   
               
               
                 Phe Leu Lys Asn-NH 2   
               
             
          
         
       
     
         [0377]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.) cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3159.4. 
       EXAMPLE 157 
     Preparation of Peptide Having SEQ ID NO: 157 
       [0378]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:157] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Asp Trp Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0379]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3200.6. 
       EXAMPLE 158 
     Preparation of Peptide Having SEQ ID NO: 158 
       [0380]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:158] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Asp Phe Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0381]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3143.5. 
       EXAMPLE 159 
     Preparation of Peptide Having SEQ ID NO: 159 
       [0382]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:159] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Ala Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0383]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3099.5. 
       EXAMPLE 160 
     Preparation of Peptide Having SEQ ID NO: 160 
       [0384]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:160] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Ala Leu 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0385]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3081.4. 
       EXAMPLE 161 
     Preparation of Peptide Having SEQ ID NO: 161 
       [0386]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:161] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Ala 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0387]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3172.5. 
       EXAMPLE 162 
     Preparation of Peptide Having SEQ ID NO: 162 
       [0388]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 162] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Ala 
               
               
                   
               
               
                 Lys Asn-NH 2   
               
             
          
         
       
     
         [0389]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3115.5. 
       EXAMPLE 163 
     Preparation of Peptide Having SEQ ID NO: 163 
       [0390]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 163] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Ala Asn-NH 2   
               
             
          
         
       
     
         [0391]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3157.5. 
       EXAMPLE 164 
     Preparation of Peptide Having SEQ ID NO: 164 
       [0392]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 164] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Ala Asn-NH 2   
               
             
          
         
       
     
         [0393]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3100.4. 
       EXAMPLE 165 
     Preparation of Peptide Having SEQ ID NO: 165 
       [0394]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 165] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Ala-NH 2   
               
             
          
         
       
     
         [0395]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3171.6. 
       EXAMPLE 166 
     Preparation of Peptide Having SEQ ID NO: 166 
       [0396]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 166] 
                   
               
             
          
           
               
                 Ala Gly Asp Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Ala-NH 2   
               
             
          
         
       
     
         [0397]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3114.5. 
       EXAMPLE 167 
     Preparation of Peptide Having SEQ ID NO: 167 
       [0398]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 167] 
                   
               
             
          
           
               
                 Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro-NH 2   
               
             
          
         
       
     
         [0399]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4033.5. 
       EXAMPLE 168 
     Preparation of Peptide Having SEQ ID NO: 168 
       [0400]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 168] 
                   
               
             
          
           
               
                 His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro-NH 2   
               
             
          
         
       
     
         [0401]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3984.4. 
       EXAMPLE 169 
     Preparation of Peptide Having SEQ ID NO: 169 
       [0402]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 169] 
                   
               
             
          
           
               
                 His Gly Glu Ala Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro-NH 2   
               
             
          
         
       
     
         [0403]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4016.5. 
       EXAMPLE 170 
     Preparation of Peptide Having SEQ ID NO: 170 
       [0404]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 170] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Ala Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro-NH 2   
               
             
          
         
       
     
         [0405]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3861.3. 
       EXAMPLE 171 
     Preparation of Peptide Having SEQ ID NO: 171 
       [0406]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 171] 
                   
               
             
          
           
               
                 Ala Gly Glu Gly Thr Phe Thr Ser Asp Ala Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro-NH 2   
               
             
          
         
       
     
         [0407]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3746.1. 
       EXAMPLE 172 
     Preparation of Peptide Having SEQ ID NO: 172 
       [0408]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 172] 
                   
               
             
          
           
               
                 Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser Ser Gly Ala-NH 2   
               
             
          
         
       
     
         [0409]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3742.1. 
       EXAMPLE 173 
     Preparation of Peptide Having SEQ ID NO: 173 
       [0410]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 173] 
                   
               
             
          
           
               
                 His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser Ser Gly Ala-NH 2   
               
             
          
         
       
     
         [0411]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3693.1. 
       EXAMPLE 174 
     Preparation of Peptide Having SEQ ID NO: 174 
       [0412]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 174] 
                   
               
             
          
           
               
                 His Gly Glu Ala Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser Ser Gly-NH 2   
               
             
          
         
       
     
         [0413]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3751.2. 
       EXAMPLE 175 
     Preparation of Peptide Having SEQ ID NO: 175 
       [0414]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 175] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Ala Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser Ser-NH 2   
               
             
          
         
       
     
         [0415]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3634.1. 
       EXAMPLE 176 
     Preparation of Peptide Having SEQ ID NO: 176 
       [0416]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO: 176] 
                   
               
             
          
           
               
                 Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser-NH 2   
               
             
          
         
       
     
         [0417]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3526.9. 
       EXAMPLE 177 
     Preparation of Peptide Having SEQ ID NO: 177 
       [0418]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:177] 
                   
               
             
          
           
               
                 His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser-NH 2   
               
             
          
         
       
     
         [0419]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3477.9. 
       EXAMPLE 178 
     Preparation of Peptide having SEQ ID NO: 178 
       [0420]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:178] 
                   
               
             
          
           
               
                 His Gly Glu Ala Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro-NH 2   
               
             
          
         
       
     
         [0421]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3519.9. 
       EXAMPLE 179 
     Preparation of Peptide Having SEQ ID NO: 179 
       [0422]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:179] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Ala Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly-NH 2   
               
             
          
         
       
     
         [0423]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3307.7. 
       EXAMPLE 180 
     Preparation of Peptide Having SEQ ID NO: 180 
       [0424]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:180] 
                   
               
             
          
           
               
                 Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn Gly-NH 2   
               
             
          
         
       
     
         [0425]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3186.5. 
       EXAMPLE 181 
     Preparation of Peptide Having SEQ ID NO: 181 
       [0426]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:181] 
                   
               
             
          
           
               
                 His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly tPro Ser Ser Gly Ala tPro tPro 
               
               
                   
               
               
                 tPro-NH 2   
               
             
          
         
       
     
         [0427]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Double couplings are required at residues 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4121.1. 
       EXAMPLE 182 
     Preparation of Peptide Having SEQ ID NO: 182 
       [0428]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:182] 
                   
               
             
          
           
               
                 His Gly Glu Ala Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser Ser Gly Ala tPro tPro 
               
               
                   
               
               
                 tPro-NH 2   
               
             
          
         
       
     
         [0429]    The above-identified amidated peptide is assembled on 4-(21-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Double couplings are required at residues 37, 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4173.2. 
       EXAMPLE 183 
     Preparation of Peptide Having SEQ ID NO: 183 
       [0430]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:183] 
                   
               
             
          
           
               
                 His Gly Glu Gly Thr Phe Thr Ser Ala Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly NMeala Ser Ser Gly Ala NMeala 
               
               
                   
               
               
                 NMeala-NH 2   
               
             
          
         
       
     
         [0431]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Compound 1. Double couplings are required at residues 36 and 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC. (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3796.1. 
       EXAMPLE 184 
     Preparation of Peptide Having SEQ ID NO: 184 
       [0432]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:184] 
                   
               
             
          
           
               
                 Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly hPro Ser Ser Gly Ala hPro-NH 2   
               
             
          
         
       
     
         [0433]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. A double coupling is required at residue 31. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3871.1. 
       EXAMPLE 185 
     Preparation of Peptide Having SEQ ID NO: 185 
       [0434]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:185] 
                   
               
             
          
           
               
                 His Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser Ser Gly Ala-NH 2   
               
             
          
         
       
     
         [0435]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3750.2. 
       EXAMPLE 186 
     Preparation of Peptide Having SEQ ID NO: 186 
       [0436]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:186] 
                   
               
             
          
           
               
                 His Gly Asp Ala Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly-NH 2   
               
             
          
         
       
     
         [0437]    The above-identified amdiated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 3408.8. 
       EXAMPLE 187 
     Preparation of Peptide Having SEQ ID NO: 187 
       [0438]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:187] 
                   
               
             
          
           
               
                 Ala Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro 
               
               
                   
               
               
                 Ser-NH 2   
               
             
          
         
       
     
         [0439]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4120.6. 
       EXAMPLE 188 
     Preparation of Peptide Having SEQ ID NO: 188 
       [0440]      
         [0000]    
       
         
               
               
             
               
               
             
           
               
                 [SEQ ID NO:188] 
                   
               
             
          
           
               
                 Ala Gly Ala Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln 
                   
               
               
                   
               
               
                 Leu Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Phe Leu 
               
               
                   
               
               
                 Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro 
               
               
                   
               
               
                 Ser-NH 2   
               
             
          
         
       
     
         [0441]    The above-identified amidated peptide is assembled on 4-(2′-4′-dimethoxyphenyl)-Fmoc aminomethyl phenoxy acetamide norleucine MBHA resin (Novabiochem, 0.55 mmole/g) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry (M): calculated 4005.5. 
       EXAMPLE 189 
     Preparation of C-Terminal Carboxylic Acid Peptides Corresponding to the C-Terminal Amide Sequences for Peptides Having SEQ ID NOs. 100-166, 172-177, 179-180 and 185-188 
       [0442]    C-terminal carboxylic acid peptides corresponding to amidated having SEQ ID NOs. 100-166, 172-177, 179-180 and 185-188 are assembled on the so called Wang resin (p-alkoxybenzylalacohol resin (Bachem, 0.54 mmole/g)) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to that described in Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry provides an experimentally determined (M). 
       EXAMPLE 190 
     Preparation of C-Terminal Carboxylic Acid Peptides Corresponding to the C-Terminal Amide Sequences for Peptides Having SEQ ID NOs. 167-171, 178 and 181-184 
       [0443]    C-terminal carboxylic acid peptides corresponding to amidated SEQ ID NOs. 167-171, 178 and 181-184 are assembled on the 2-chlorotritylchloride resin (200-400 mesh), 2% DVB (Novabiochem, 0.4-1.0 mmole/g)) using Fmoc-protected amino acids (Applied Biosystems, Inc.), cleaved from the resin, deprotected and purified in a similar way to that described in Example 100. Used in analysis are Solvent A (0.1% TFA in water) and Solvent B (0.1% TFA in ACN). Analytical RP-HPLC (gradient 30% to 60% Solvent B in Solvent A over 30 minutes) of the lyophilized peptide is then carried out to determine the retention time of the product peptide. Electrospray Mass Spectrometry provides an experimentally determined (M). 
         [0444]    Various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the following claims. 
         [0445]    All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.